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Abstract 
The study of protein-ligand and protein-protein interactions is of paramount 
importance to the understanding of their biological function. Whereas this area of 
research has been largely dominated by conventional structural biology 
techniques, such as NMR and X-ray crystallography, an emerging methodology 
that relies on the implementation of hydrogen deuterium exchange (HDX) 
powered by MS-based analysis holds the potential to greatly expand on our 
ability to probe the protein dynamics of fundamental biological processes. In this 
work, the entire HDX workflow for site-specific analysis of protein dynamics was 
integrated onto a concerted microfluidic device and applied to the interrogation of 
the dynamic changes that accompany protein-ligand interactions. This 
application is described for two model systems: the binding of glutathione (GSH) 
by Glutathione-S-Transferase (GST), and the binding of three novel salicylic 
acid-based inhibitors of Signal Transducer and Activator of Transcription 3 
(STAT3) to its SH2 domain. This work extends the application of time-resolved 
electrospray ionization mass spectrometry (TRESI-MS) HDX to the study of 
protein ligand interaction dynamics and ligand-binding site mapping.     
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Chapter 1  
 Introduction 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter was published in FEBS Journal: 
Resetca, D. and D. J. Wilson (2013). "Characterizing rapid, activity-linked 
conformational transitions in proteins via sub-second hydrogen deuterium exchange 
mass spectrometry." FEBS J 280(22): 5616-5625. 
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1.1 Summary 
This review outlines the application of Time-Resolved ElectroSpray Ionization Mass 
Spectrometry (TRESI-MS) and hydrogen-deuterium exchange (HDX) to study rapid, 
activity-linked conformational transitions in proteins. The method is implemented on a 
microfluidic chip, which incorporates a capillary mixer for sub-second HDX labeling, a 
microreactor for rapid protein digestion, and on-chip electrospray. By combining short 
HDX labeling pulses with rapid digestion, this approach can provide a detailed 
characterization of the structural transitions that occur during protein folding, ligand 
binding, post-translational modification, and catalytic turnover in enzymes. This broad 
spectrum of applications in areas largely inaccessible to conventional techniques makes 
microfluidics-enabled TRESI-MS/HDX a unique and powerful approach for investigating 
the fundamental dynamic basis of protein function. 
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1.2 Characterizing Protein Dynamics 
1.2.1 Current Analytical Techniques for the Characterization of Protein 
Dynamics 
Molecular dynamics play a fundamental role in ensuring proper protein function, from 
protein folding to enzyme catalysis to the more complex protein-protein interactions. 
The study of protein conformational ensembles, and how they evolve and shift upon 
interaction with other molecules, has helped rationalize the concepts of allosteric 
regulation, induced-fit binding and conformer selection. The examination of protein 
dynamics has contributed to the understanding of many aspects of basic protein 
function that cannot be explained using static, ground state representations of proteins. 
The latter merely capture the start and end results of a process, rather than the complex 
pathway of a series of fluctuations from equilibrium and conformer selection steps that 
the protein navigates through. Observation of protein dynamic changes necessitates the 
use of bioanalytical techniques that are capable of capturing and dissecting the 
broadest range of conformational transitions across the entire energetic landscape 
accessible to the protein. Thus, the most robust technique should permit the probing of 
large conformational ensembles of both stable, ground states, as well as sparsely 
populated, excited and transition states, with high structural resolution. One rapidly 
advancing technique that has the potential to greatly satisfy these criteria is structural 
mass spectrometry.  
Conventional structural biology techniques, like X-ray crystallography and structural 
NMR, have greatly advanced our understanding of protein structures, protein 
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interactions and catalysis using static representations of typically low energy state 
conformers, but are generally ill-suited to the study of transient intermediates and 
excited species (1-4). Analyzing short-lived intermediates of proteins as they transition 
between states, whether in protein folding, enzyme catalysis or protein-protein 
interactions, has proven a major challenge in analytical biochemistry. As a result, there 
is a substantial gap in our understanding of the dynamic processes that underlie 
protein-mediated biological function in the cell.  
The occurrence of short-lived protein intermediates has been demonstrated by a variety 
of spectroscopic methods, including circular dichroism (CD) (5,6), fluorescence-based 
assays (7), and NMR spectroscopy (8,9). These methods have been widely used for the 
interrogation of changes in protein dynamics, but each approach has a restricted 
applicability in conducting kinetic experiments that can provide structural and/or 
mechanistic insights.  
Parameters derived through the various analytical techniques have also enabled the 
application of a vast number of computational tools for the theoretical study of protein 
dynamics (10). However, current in silico simulations are still greatly limited by 
processing power, where the accuracy of predictions trade off with the complexity of the 
models and the built-in parameters (11,12). 
1.2.2 Analysis of Protein Dynamics by CD 
Circular dichroism is an analytical technique with some utility in the study of protein 
secondary structure composition. Optically active chromophores, such as peptide 
bonds, posses an intrinsic ability to differentially absorb left and right circularly polarized 
light when placed in the plane polarised environment. Thus, regular secondary structure 
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features such as α-helices and β-sheets can be evaluated and differentiated in the far 
UV region (180-240 nm) as a characteristic elliptical polarization. CD spectroscopy is a 
useful method for monitoring protein unfolding, or melting, allowing one to discern 
changes in secondary and tertiary structures of proteins, and, in certain cases, even for 
examining protein-protein interactions (13,14). However, quantitative structural 
interpretation of the CD spectra is at best limited to an 'aggregate' measurement of 
secondary structure and is reliant on calibration to known structures. Additionally, CD 
spectra yield no site-specific information of protein secondary structure and lack the 
ability to distinguish multiple, sparsely populated conformational states.   
1.2.3 Analysis of Protein Dynamics by FRET  
Fluorescence-based methods, particularly Forster Resonance Energy Transfer (FRET), 
have been widely applied in time-resolved studies of enzyme catalysis and protein-
ligand interactions and offer a large sensitivity range (15). The FRET technique typically 
involves two fluorophores or a fluorophore and quencher, each tagged to a separate 
analyte. Excitation of the first fluorophore results in a fluorescence emission in the 
excitation range of the second fluorophore, resulting in its bystander excitation, or, in the 
case of a quencher, the suppression of fluorescent signal. The efficiency of this energy 
transfer is inversely proportional to the distance between the two fluorophores. 
Therefore, this technique is highly applicable to the probing of protein-protein 
interactions. However, FRET-based experiments provide limited structural insights, 
usually in the form of single inter-probe distance measurements, whose biological 
significance is somewhat reduced by the presence of the FRET probes themselves in 
the protein (16).  
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1.2.4 Analysis of Dynamics by NMR 
From amongst the various spectroscopic techniques applied in analytical biochemistry, 
NMR spectroscopy has made the largest contribution to studies of protein structure in 
solution. In application to protein, NMR takes advantage of the presence of 
paramagnetic nuclei with angular spin momentum in biological macromolecules. In high, 
static magnetic field, spin energy levels of such nuclei tend to split due to the Zeeman’s 
effect (17). In nuclei with a spin of I = ½, the splitting results in equally spaced energy 
levels with two possible values for the magnetic quantum number (m = ½ or -½) (18). 
Application of electromagnetic radiation in the radio frequency range can drive nuclear 
transitions between the two energy levels. Each nucleus will absorb and resonate at a 
specific frequency as a function of the local environment. In pulsed NMR, applied as 
part of the broadband radio frequency pulse, such radio frequency excites the 
corresponding nuclei to populate the highest energy spin level resulting in the inversion 
of the nuclear spin. The nuclear magnetization then relaxes back to the ground state, 
precessing around the magnetic field vector at a specific precession frequency, known 
as the Larmor frequency, which can be detected by the radio frequency receiver coil of 
the instrument (17). The Larmor frequency for each nucleus is strongly influenced by 
the surrounding environment, specifically, shielding by localized magnetic fields of 
nearby electrons. The diverse chemical environment of each nucleus will cause the 
frequency at which it resonates to be slightly different, reflected as a shift in the peaks of 
the NMR spectrum, known as a chemical shift δ (17). This quantity is relative and is 
independent of the strength of the static magnetic field of the instrument, and different 
atomic nuclei are influenced by their chemical environment to varying extents. In 
biological macromolecules, 1H, 13C, and 15N nuclei are readily available to analysis by 
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NMR, and are either highly abundant naturally or can be enriched for in recombinantly 
expressed molecules. The relaxation times of the various nuclei are simultaneously 
detected as a signal image current by the NMR receiver coil in the time domain, which 
can be Fourier transformed into the frequency domain. The Fourier transformed NMR 
spectrum enables resolving the individual signals corresponding to each relaxing 
nucleus. An important characteristic of NMR spectra, which aids in the interpretation of 
the structure of the analyte molecule, is that the area under curve of each peak is 
proportional to the number of the nuclei resonating at the same frequency. Another 
NMR phenomena that is crucial in aiding the interpretation of the analyte molecule 
structure is scalar coupling between nuclei that are covalently bonded and separated by 
up to 4 covalent bonds, also known as J-coupling. This coupling effectively results in a 
splitting of the energy level populated by a particular nucleus, which ultimately 
translates into additional chemical shifts (J-constant in Hz) and manifests as a multiplet 
of peaks on the NMR spectrum. The resulting, complex multiplets can be interpreted for 
each nucleus with respect to its covalent bond assignment. Yet another phenomena, 
known as the Nuclear Overhauser Effect (NOE), which is a form of dipolar coupling 
taking place between nuclei that are very close spatially (less than a few Å), is 
invaluable in interpreting distance constraints in structural analysis of proteins. The NOE 
NMR experiment, which can be performed in two dimensions, permits the determination 
of a distance constraint matrix for each excitable nucleus. The introduction of variable 
delay into the complex pulse sequence also referred to as evolution time permits the 
generation of two-dimensional spectra, which greatly simplifies the interpretation of 
highly complex molecular structures compared to a one-dimensional experiment. Most 
popular multi-dimensional NMR experiments are correlation spectroscopy (COSY), 
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which relies on scalar J-couplings, and nuclear Overhauser effect spectroscopy 
(NOESY), which relies on dipolar couplings, with the latter particularly useful for the 
interpretation of distance constraints in protein structures. Finally, additional significant 
structural information helpful in the interpretation of protein structures can be derived 
form heteronuclear NMR experiments, whereby 1H scalar coupling to the 13C and 15N 
nuclei could be detected and interpreted with respect to structural distance constraints 
(17,18).   
Some of the practical advantages of NMR are that the experiments can be conducted 
on native proteins in solution and are non-destructive to the analyte. This facilitates the 
use of NMR for the study of protein dynamics under physiological conditions. 
Importantly, hydrogen deuterium exchange (HDX) experiments, described in detail in 
the subsequent sections, can also be analyzed by NMR owing to the fact that deuterium 
(2H) nuclei are not visible to NMR (17). However, applications of NMR in kinetic studies 
of transient protein states are generally restricted by the relative insensitivity of the 
technique (requiring mid- to high-µM concentrations) and the size limit of proteins that 
can be analyzed (typically, subunit size of less than 70kDa with the use of TROSY) (19). 
Conducting time-resolved kinetic experiments in real-time with the application of NMR 
on the sub-second timescale is practically challenging, requiring complex pulse 
sequences with greatly diminished sensitivity. One methodology that has been 
developed for real-time NMR studies relies on photo-labile “caged” compounds (20), but 
the experimental set-up is complex, requires the design and synthesis of “caged” 
ligands, making the overall approach far from universally applicable. 
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Recent developments in biophysical NMR methods have allowed some insight into 
millisecond-timescale conformational dynamics of proteins. In particular, Carr-Purcell-
Meiboom-Gill (CPMG) relaxation dispersion allows for the site-specific characterization 
of the kinetic and thermodynamic properties of nuclei on the microsecond-millisecond 
timescale as they sample different environments during conformational exchange (21). 
However, continuous presence of the species/conformational states analyzed 
throughout the time-window of the relaxation dispersion experiment is needed, and 
these experiments will thus be typically limited to systems at equilibrium (22). 
Furthermore, systems exchanging between more than two states are difficult to 
characterize by CPMG experiments (23). 
1.3 Analysis of Protein Dynamics by Mass Spectrometry 
1.3.1 Label-Free Analysis of Protein Structure by Mass Spectrometry 
The intrinsic analytic capabilities of mass spectrometry are of limited utility on their own 
in the study of protein structure and dynamics, but can be greatly expanded by a 
number of complementary methods for probing protein dynamics. One direct method is 
based on the propensity of more unfolded proteins to acquire more charges in the 
process of electrospray ionization (24). The resulting distribution of multiply charged 
ions in the mass spectrum will reflect the extent of protein unfolding, but this information 
is also limited to the overall three-dimensional packing of the protein. 
Ion mobility-mass spectrometry is also emerging as a label-free technique for structural 
analysis in the gas phase. In this experiment, a weak electrostatic field is applied across 
the ion drift space, influencing macromolecular ions to separate based on their drift 
velocities (25). Ions sample different possible geometric orientations as they proceed 
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through the drift tube, and, in the presence of a neutral background gas, 
macromolecular ions possessing different sizes and geometries pass through the drift 
region at different velocities. The results are collisional cross sections that vary with the 
three-dimensional organization of the ions (26). Therefore, ion mobility spectrometry 
can provide information on the overall three-dimensional packing of the protein and can 
easily differentiate between folded and loosely-folded states, but provides no true 
structural resolution. 
1.3.2 Hydrogen-Deuterium Exchange (HDX) for the Analysis of Protein 
Dynamics 
Mass spectrometry with HDX has recently emerged as a powerful tool in structural 
biology, especially in the context of high-throughput structural proteomics (27). Mass 
spectrometry offers the capability to conduct millisecond-timescale measurements (28), 
in addition to high sensitivity, and the potential for direct in-line coupling to a variety of 
liquid chromatography (LC) and microfluidic devices (29), allowing kinetic experiments 
to be implemented with ease (30,31). Electrospray ionization (ESI) and matrix-assisted 
laser desorption/ionization (MALDI) methods enable the analysis of whole proteins of 
any size, and protein complexes larger than 1 MDa have been successfully analyzed 
(32,33). HDX experiments in conjunction with MS-based analysis permit simultaneous 
structural and kinetic analyses, enabling complex protein energy landscapes to be 
mapped in protein folding and enzyme catalysis (34-36).  
The advance that significantly enhanced MS-based analysis of protein dynamics is 
isotope incorporation by means of HDX (37). This approach has been extensively 
reviewed (e.g., (38)) and is briefly described below. HDX relies on the ability of 
hydrogen atoms to undergo exchange with deuterons from solvent (or surrounding gas), 
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resulting in the incorporation of deuterium at accessible sites of the macromolecule. In 
solution, HDX is base-catalyzed (though general acid catalysis becomes dominant at 
pH < 2.6). The rate of HDX at individual sites is dependent on a multitude of factors, 
including the character of the functional group, accessibility to the exchange reagent, 
degree of hydrogen bonding of the labile hydrogen, and the nature of deuterium donor 
that dictates the exchange mechanism (i.e., salt bridge, tautomer, onium ion, flip-flop, 
and relay mechanisms) (39).   
Hydrogen exchange takes place from a hydrogen donor (A-H) to a hydrogen acceptor 
(B). In biological macromolecules, such as proteins, hydrogen exchange is either driven 
by strong base OH- and strong acid H3O+ catalysis. The mechanism of the exchange 
reaction, as depicted in Fig. 1A, occurs via the formation of a collision complex followed 
by rapid equilibration of the proton across the hydrogen bridge, followed by the 
dissociation of the new hydrogen-bonded complex (40). The direction of the proton 
transfer reaction is from a strong acid to a weaker acid, and is determined by the rate 
constant of the exchange, which is governed by the diffusion limit (k1). Alternatively, an 
exchange reaction from a weak acid to a strong base occurs only in a small fraction of 
productive collisions, is influenced by the environment of the backbone amides in the 
polyamide chain, and is governed by the exchange rate constant k = 
k1(10ΔpK/(10ΔpK+1)), where k1 is the diffusion-limited collision rate constant and ΔpK is 
the difference between the pK of the acceptor and the donor (41). Amide hydrogens in 
the peptide backbone can undergo slower exchange than the polar hydrogens of the 
side chains or N- and C- termini, which exchange easily. The pK parameter is the rate-
determining step in the exchange reaction of backbone amides, which have a high 
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deprotonation pK value of ~18, much higher than the pK of side-chain exchangeable 
protons, which is typically less than 13 and is highly reactive with the hydroxyl base at 
neutral pH. Thus, owing to their slower rate of exchange, backbone amide hydrogens 
are exceedingly good probes of secondary structure of proteins and are present in 
every amino acid, but proline (42).  
While backbone amide hydrogen exchange can proceed by several mechanisms, under 
physiological conditions, amide hydrogen exchange proceeds via base catalysis (Fig. 
1B) as proposed by Berger and coworkers in 1959 based on the proteolysis and 
ionization results of N-methylacetamide (43). The first step of the exchange reaction is 
the abstraction of the amide proton by the deuterium hydroxide ion and formation of an 
imidate anion. Reprotonation of the imidate anion by a deuteron subsequently leads to 
the completion of exchange transfer reaction. This direct mechanism of amide proton 
exchange is highly influenced by the particular environment of the peptidic bond in the 
protein structure. A number of factors affect hydrogen deuterium rate of exchange, with 
the pH being of paramount importance. Studies of hydrogen deuterium exchange in 
random coil-like poly-DL-alanine peptide (PDLA) revealed a quantitative dependence of 
the amide proton exchange rate on the pH (44). Bai et al. established the contributions 
of each of the components on the overall rate of exchange in PDLA in acidic and basic 
solutions and concluded that the rate of exchange was proportional to the concentration 
of the acid and base catalysts (45). The overall rate of exchange of free amide in 
solution, kex, can be summarized as a sum of the contributions from water- (kwater), acid- 
(kH3O+), and base- (kOH-) catalyzed rate constants (kex = kwater + kH3O+ [H3O+]+ kOH- [OH-] 
or log (kex) = log (kwater + k H3O+ [H3O+]+ kOH- [OH-])) (45-47).
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Fig. 1 The Mechanism of Hydrogen Exchange in Proteins. A) Proton transfer in the 
hydrogen exchange reaction between a hydrogen bond donor (AH) and an acceptor (B). 
A collision between a hydrogen bond donor and acceptor induces the formation of a 
hydrogen bridge, governed by the k1 rate constant (a diffusion-limited process). 
Equilibration of the proton within the hydrogen bridge is dependent on the rate constant 
k2. The release of the newly formed hydrogen complex is dependent on the rate 
constant k3. B) Base-catalyzed mechanism of hydrogen deuterium exchange of amide 
hydrogens in protein backbone. A deuterium hydroxide base attacks the covalently 
attached hydrogen at the peptide amide position, which leads to the formation of an 
imidate anion and the subsequent reprotonation of the imidate by D2O.    
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Furthermore, base catalysis of amide hydrogens is at least 8 orders of magnitude more 
effective than acid catalysis (48). The pH profile of the hydrogen exchange, plotted as 
log (kex) versus pH, is typically V-shaped, where pHmin reflects the point where acid- and 
base-catalyzed exchanges are equal. Fig. 2 depicts the hydrogen deuterium exchange 
as a function of pH as determined for backbone and side-chain amide hydrogens, 
demonstrating that a change in one pH unit is reflective of an approximately 10-fold 
change in the exchange rate. For backbone amides, pH minimum (pHmin) occurs 
approximately pH 3. Temperature and solvent composition also exert a significant effect 
on the hydrogen deuterium exchange rates (41,45,49). The temperature parameter can 
be estimated at different temperatures using the Arrhenius equation, k(x)T = k(x)T2 exp(-
Ea(x)/R[1/T-1/T2]), where x is either base-, acid-, or water-catalyzed reaction, k(x)T and 
k(x)T2 are the exchange constants at two different temperatures, R is the ideal gas 
constant, and the activation energies Ea(x) for base-, acid- and water-catalyzed 
exchanges are 17 kcal/mol, 14 kcal/mol and 19 kcal/mol, respectively (45). Temperature 
changes mainly affect the kex by altering the ionization constant of water and thus 
changing the concentration of the catalyst ([-OH] for base catalysis) (41,49). 
Additionally, the diffusion coefficient k1, describing the number of successful hydrogen-
bonded complexes forming, is significantly reduced with decreasing temperature, thus 
affecting the transfer rate between the proton donor and acceptor in the collision 
reaction, due to the increased viscosity of the solution, a parameter dependent on the 
temperature. Organic additives can also affect the effective concentration of the base 
catalyst in the hydrogen transfer reaction, and do so by depressing the equilibrium 
constant of water (Kw) or hydroxide ion activity, thus resulting in a shift of pHmin (50-52).  
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Fig. 2 Plot of log (kex) versus Solution pH in the Hydrogen Deuterium Exchange 
Reaction (Adopted from ref. (48) ). Hydrogen deuterium exchange profiles for nitrogen-
bound hydrogens in unstructured polypeptides plotted as a function of pH, where pHmin 
reflects a point of minimum exchange log (kex, min), where kacid equals to kbase. The pHmin 
of backbone amides occurs at approximately pH 3. 
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On average unstructured, fully solvent-exposed amides have been shown to exchange 
with deuterium with a kex of 101 – 103 s-1 (45). Two factors known to affect the exchange 
rate of backbone amide hydrogens in proteins are solvent accessibility of the region and 
intermolecular hydrogen bonding. The latter can significantly decrease the rate of the 
exchange reaction. In proteins, backbone amide hydrogen exchange with the deuterium 
of the solvent has been proposed to occur either directly in the folded state or first be 
preceded by partial or global unfolding, known as “breathing”, and then followed by 
deuterium exchange. The overall, experimentally-observed exchange rate (ko) can be 
characterized as a sum of two components, the exchange rate of folded (kf) and 
exchange rate of unfolded (ku) states, ko = kf +ku (46,53). Fig. 3 depicts the current 
understanding of deuterium exchange in proteins, comprising a two-state model, 
whereby the exchange occurs in either the folded or partially unfolded species. In the 
folded-state model (Fig. 3A), the exchange is suggested to be limited by solvent 
diffusion into the core of the protein and governed by kf = βkex, where kex is the rate 
constant of the exchange of the backbone amides in an unstructured polypeptide and 
β is the probability of backbone amide being exposed to both catalyst and water (54). 
Thus, hydrogens which are on the protein surface or in proximity to solvent channels 
are thought to readily exchange in the presence of a catalyst, while buried amide 
hydrogens exchange as a function of the dynamic solvent accessibility due to hydrogen 
bond reorganization through short and transient molecular motions. Additionally, 
Tuchsen and Woodward proposed that amide hydrogens which take part in hydrogen 
bonding with the solvation shell of the protein primarily exchange at the surface, while 
the core portion of the protein undergoes exchange by a relay mechanisms from the 
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surface, as a function of pH (55,56). In the partially unfolded state model (Fig. 3B), 
exchange rate is ku = kex(k1/(k-1+kex)), and in native proteins is thought to proceed 
through extended “breathing” motions that result in partial unfolding and refolding 
events governed by the k1 and k-1 rate constants, respectively, and an intrinsic 
exchange rate constant in the unfolded state described by kex (57,58). In general, 
proteins in their native state are thought to experience very small relative rates of 
unfolding and refolding, where the rate of the unfolding dynamics is very fast (k1<<k-1), 
and this is known as the EX2 kinetics (Fig. 3B and C), where the rate limiting step for 
hydrogen deuterium exchange is governed by the kex. Additionally, although observed 
very rarely in proteins, the exchange can proceed via EX1 kinetics, where the hydrogen 
exchange is preceded by a slow, global unfolding compared to refolding (k1>>k-1) (59). 
While EX2 kinetics shows a high dependence on the pH and is reflective of the native 
protein conformation, EX1 kinetics proceed independently of the pH and reflect a 
cooperative exchange mode that can be facilitated by denaturing conditions. Thus, in 
backbone amides of proteins, the observed exchange rate constant (ko) at a steady-
state can be described by a composite of both folded and partially-unfolded models, 
with ko = kex (β + k1/k-1), where either EX1 or EX2 kinetics or a combination of both can 
be observed. 
The ability of MS to accurately resolve mass shifts associated with the appearance of 
deuterated species makes this analytical method highly suitable for and efficient in the 
analysis of HDX experiments. Furthermore, MS enables the measurement of both 
global as well as site-specific HDX in biological macromolecules. 
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Fig. 3 Mechanistic Models of Backbone Amide Exchange in Proteins. A) Folded protein 
backbone amides exchange (FH ! FD) with deuterium solvent with the rate constant kf = 
βkex. B) Local unfolding, “breathing” motions and global unfolding of the protein result in 
the backbone amide exchange (FH ! UH ! UD ! FD) with deuterium solvent with the 
rate constant ku = kex(k1/(k-1+kex)). C) Conditions for EX1 and EX2 exchange kinetics. 
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 MS-based HDX measurements can be implemented 'globally' to give information on the 
overall flexibility of proteins (relevant to protein stability under specific conditions) or 
'locally' to distinguish regions exhibiting varying degrees of protection from exchange 
due to structure. 'Global' measurements are made simply by exposing the protein to 
D2O for a variable period of time, followed by online or offline MS analysis to measure 
the increasing mass associated with deuterium uptake. To achieve spatial resolution 
(i.e., 'local' measurements), the HDX process can be quenched using low pH conditions 
(the average minimum rate for HDX occurs at pH ~ 2.6) followed by enzymatic digestion 
by an acid protease and analysis of differentially-labeled peptides. This is known as a 
'bottom-up' workflow. Alternatively, non-ergodic fragmentation techniques such as 
Electron Capture Dissociation (ECD) can be used to fragment the labeled protein in the 
gas phase (known as a 'top-down' workflow). Either of these approaches can achieve 
spatial resolution down to the near-single amino acid level (35,36). 
1.3.3 Time-resolved electrospray mass spectrometry with HDX 
Time-Resolved ElectroSpray Ionization mass spectrometry (TRESI-MS) allows for the 
detection of full-length, native proteins in kinetic experiments in which virtually all mass-
distinguishable species can be monitored simultaneously (60-62). In the study of 
enzyme catalysis, TRESI-MS has proven to be a remarkably enabling technology, 
allowing a nearly universal (in principle) application to the characterization of catalytic 
reaction intermediates using native enzymes and substrates (60,63). This is a 
significant improvement over standard spectroscopic techniques that rely on 
colourigenic (chromogenic) or fluorogenic substrate analogues and methods utilizing 
radioactive substrates. Applied to protein dynamics, TRESI-MS can, in combination with 
20 
 
HDX, facilitate a structural analysis of the dynamic regions of proteins undergoing 
conformational changes during biological activity (35,64). 
'Time-resolved' experiments employ rapid mixing setups to access short-timescale 
processes in (bio)chemical reactions, conventionally using NMR. NMR is a particularly 
powerful means of measuring rapid conformational dynamics, with experimental 
approaches that include stopped-flow or quench-flow rapid mixing (65,66) or equilibrium 
methods (e.g., CPMG relaxation dispersion) (67). The primary advantage of NMR-
based measurements is that data are (almost) always site specific, which can allow for 
semi-quantitative analyses of local structural stability. However, NMR has a number of 
inherent drawbacks that limit applicability to large proteins and dynamics on certain 
timescales. Lengthy data acquisition times in multidimensional NMR also represent a 
challenge in the application to time-resolved measurements, particularly in the case of 
physiological pH HDX, in which exchange processes often go to completion within a few 
seconds of exposure to D2O.  
1.3.4 Capillary-based Rapid Mixer for Millisecond-Timescale HDX 
A number of devices have been developed to couple mass spectrometry with rapid 
mixing including pulsed-flow, stopped-flow and quench-flow setups (68-70). Wilson and 
Konermann adapted continuous-flow rapid mixing for MS using a concentric capillary 
device with an automatically adjustable reaction chamber volume (Fig. 4A) (28). 
Solutions are supplied to each of the capillaries at the inlet by infusion pumps, 
generating a continuous laminar flow. One of the key advantages of this apparatus is 
that the outer capillary can be used as the ion source, resulting in a minimum reaction 
volume of 0 µL and a dead-time governed exclusively by the mixing volume 
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(corresponding to approximately 8 nL). The approach requires a custom 'front-end' 
(usually a straightforward modification of the commercial nanospray source) and the 
application of a laminar-flow corrected analytical framework to extract accurate rate 
parameters from the data. A detailed treatment of the theory underlying capillary mixer 
data analysis can be found in the original publication (28).  
TRESI-MS with HDX provides a unique and powerful approach for conducting 
continuous-flow HDX experiments outside of the constrained time-window accessible to 
studies employing the conventional adapted LC setup. The capacity of TRESI-MS/HDX 
to generate short (ms) labeling pulses confers the ability to analyze dynamics in weakly-
structured regions of proteins, such as molten globules, random coils and intrinsically 
disordered domains. For the added capability of measuring site-specific exchange, the 
labeled products can be subsequently fragmented or digested (29). This is a significant 
improvement over conventional LC-based methods, which typically achieve minimum 
labeling times of 1 second at best, with a substantial delay between labeling and 
analysis (71). In the case of a 'bottom-up' approach, the outlet of the capillary mixer can 
be coupled to a microfluidic chip that handles subsequent sample processing (Fig. 4B). 
This includes the introduction of low pH solution for HDX quenching, and proteolysis in 
a pepsin-functionalized reaction chamber (29,35). Oxidative labeling is a 
complementary structural method that has also been linked to TRESI (72). This 
approach involves the covalent attachment of a non-labile label to redox-active amino 
acid side-chains, eliminating the back-exchange issue, which can occur in HDX. In 
contrast to HDX, influenced by both hydrogen bonding and solvent access, oxidative 
labeling efficiency is linked specifically to solvent accessibility and is typically much 
lower resolution (since it can only be measured at redox active side-chains) (73).
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Fig. 4 Schematic of the Microfluidic-Based Rapid-Mixing Device for TRESI-MS/HDX 
Experiments. A) Schematic depiction of a Capillary-based rapid mixer with adjustable 
reaction chamber volume. An inner fused silica capillary is inserted through an outer 
metal capillary of larger diameter through a three-way union. Two different solutions, 
one containing the protein and the second a deuterium donor, are supplied at the inlets 
of the capillaries by automated Hamilton syringes at rates maintaining laminar flow 
throughout the apparatus. A small notch, about 2 mm away from the plugged end of the 
inner capillary, enables the solution from the inner capillary to escape and mix rapidly 
with the solution in the outer capillary in the inter-capillary space. The region between 
the notch and the outlet of the apparatus at the end of the outer capillary represents the 
reaction chamber volume. The outer capillary is used as an ESI source. B) Microfluidic 
chip for site-specific HDX experiments is diagrammed. The capillary-based rapid mixer 
is integrated onto the PMMA chip, which is additionally equipped with downstream 
supply channels for the HDX quenching solution and a further downstream microreactor 
for proteolytic digestion of HDX-labelled products. The microreactor chamber is filled 
with an immobilized pepsin bead bed or another protease. The outlet of the microfluidic 
chip is connected on-line to the ESI. 
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1.3.5 Global analysis of protein folding using TRESI-MS/HDX 
Perhaps the most straightforward application of TRESI-MS/HDX is in the study of 
protein folding. The first such study was conducted by Pan et al. (74), in which a pulse-
labeling approach was used to identify a 'hidden' intermediate in the ubiquitin folding 
pathway that could only be detected by considering both the HDX and charge-state 
characteristics simultaneously. This folding intermediate had a 'native-like' most 
prevalent charge state of 5+, but acquired deuterium in a manner analogous to the 
unfolded species (Fig. 5A). As the folding reaction progressed, the 5+ peak transitioned 
from this intermediate to a species that acquired substantially less deuterium, indicating 
a more folded, native configuration. The authors were thereby able to propose a 
multistep mechanism for ubiquitin folding (Fig. 5B) and to provide evidence for the 
common occurrence of folding intermediates, even for small proteins generally assumed 
to be 'two-state' folders. 
The work by Simmons et al. 2004, exemplifies another application of TRESI-MS to the 
study of protein dynamics on the millisecond timescale (34). The authors have used the 
online rapid mixing device to monitor the kinetics of hemoglobin denaturation induced 
by the addition of acetic acid. As early as 9 ms of exposure to acid, changes in the 
profile of the observed ionic species were detected reflecting the appearance of 
different hemoglobin unfolding intermediates. The method enabled authors to detect 
short-lived unfolding intermediates on the sub-second timescale, and determine the 
order of reaction steps in the different mechanistic pathways of haemoglobin (Hb) 
denaturation by fitting the kinetic data (34). Different quaternary intermediates could be 
detected as either having a different subunit composition or losing/retaining the heme 
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prosthetic group (apo- versus holo- states) (Fig. 6). Various conformational species 
were observed based on their distinct charge distributions. The time-resolution of the 
method enabled the authors to construct a complex unfolding reaction landscape for Hb 
denaturation that involved two subpopulations of Hb tetramers that followed different 
denaturation pathways in parallel. The added advantage of the structural resolution of 
ESI-MS over other conventional methods is clearly highlighted here in its ability to 
simultaneously detect a complex mixture of quaternary and conformational species. 
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Fig. 5 TRESI-MS/HDX Study of Ubiquitin Folding Using Pulse Labeling. A) Time-
resolved mass spectra recorded at 0 ms, 40 ms, 240 ms and 3.3 s by row, top to 
bottom. Right column is an overlay of the 5+ and 9+ peak mass shifts. B) A schematic 
depiction of the proposed ubiquitin folding pathway. The intermediate species D* can 
only be detected by considering both the charge state distribution and HDX. Reprinted 
with permission from (74). © 2005 American Chemical Society. 
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Fig. 6 TRESI-MS Study of the Acid-Induced Denaturation of Hemoglobin. Shown are 
amplitude spectra for the exponential relaxation times observed during the acid-induced 
denaturation, obtained by global data analysis by regression of kinetic data. Positive 
amplitudes correspond to the occurrence of species decay or a lag phase, while 
negative amplitudes represent species formation. Reprinted with permission from (34). 
Copyright 2012 American Chemical Society. 
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1.3.6 TRESI-MS/HDX in the study of catalysis-linked dynamics in 
enzymes 
The microfluidics-based rapid mixing device can be successfully applied to the study of 
conformational fluctuations of proteins under non-equilibrium conditions in the context of 
TRESI-MS/HDX experiments. This method permits conformational dynamics to be 
probed in a system that is inaccessible to study by alternative methods, such as 
relaxation dispersion NMR on the millisecond timescale. Liuni et al. have utilized the 
rapid mixer to study conformational changes occurring during the catalytic turnover in 
chymotrypsin (63). The rapid mixing device was used to generate sub-second pulses of 
HDX labeling in the pre-steady state of chymotrypsin-catalyzed hydrolysis of para-
nitrophenyl acetate (pNPA). In this experimental set-up, D2O and pNPA substrate were 
supplied simultaneously into the mixing chamber of the device.  TRESI-MS permitted 
the simultaneous detection and quantification of the free enzyme and an acyl-enzyme 
intermediate, while also allowing the quantification of the rate and amplitude of global 
HDX that occurred in each of the species (63).  
Significantly higher rates of deuterium uptake were detected in the acyl-enzyme 
intermediate compared to the free enzyme, suggesting that the acyl-enzyme 
intermediate experienced higher rates of conformational sampling, yet the 
conformational space sampled by the enzyme and the acyl-enzyme intermediate was 
similar, as reflected by the comparable amplitudes of HDX observed between the two 
species (Fig. 7). In this instance, application of TRESI-MS/HDX yielded new 
mechanistic insights into the understanding of catalysis-linked dynamics, and provided 
evidence for a new model of conformer selection followed by intensified conformational 
searching during catalysis. An inherent advantage of MS-based methodology in kinetic 
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and dynamic studies of catalysis lies in its applicability to nearly any enzyme-substrate 
system, without the confines of having to use modified or unnatural substrates. 
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Fig. 7 A Heat Map Describing the Catalysis and HDX of Chymotrypsin Analyzed by 
TRESI-MS for the 20+ Charge State. The progress of catalysis can be observed as 
decreasing heat (for free enzyme) or increasing heat (for the acyl-enzyme intermediate). 
The global HDX kinetics are reflected in the rate of shift to higher m/z. Regression of the 
HDX kinetics data was achieved by plotting the position of the centroid of the peak for 
each m/z as a function of time. Filled circles (●) and open squares (□) represent the free 
protein and acyl-enzyme intermediate, respectively. Significantly higher rates of 
deuterium uptake were detected in the acyl-enzyme intermediate compared to the free 
enzyme, suggesting that the acyl-enzyme intermediate experienced higher rates of 
conformational sampling, yet the conformational space sampled by the enzyme and the 
acyl-enzyme intermediate was similar, as reflected by the comparable amplitudes of 
HDX observed between the two species. Reproduced with permission from (63). 
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1.3.7 Incorporating the HDX Workflow onto a Microfluidic Device for 
TRESI-MS/HDX Experiments 
A greater degree of characterization of conformational dynamics of proteins can be 
achieved by utilizing microfluidic device-based TRESI-MS/HDX to examine site-specific 
HDX rates. In order to accomplish this, a 'bottom-up' TRESI-MS/HDX workflow was 
implemented, which included an HDX quenching step and subsequent protein digestion, 
prior to ESI-MS. In the device introduced by Rob et al., a capillary-based rapid mixer 
was incorporated onto a polymethyl methacrylate (PMMA)-based microfluidic chip that 
was etched with additional supply channels for a quenching solution and a microreactor 
chamber for enzymatic protein digestion (Fig.4B) (35). Aqueous acetic acid (4% v/v, pH 
2.3) was used as an HDX quenching solution, rapidly dropping the rate of exchange and 
back-exchange to negligible levels. The microreactor chamber for protein digestion was 
filled with pepsin-agarose cross-linked beads immobilized onto the PMMA surface (29). 
Pepsin’s broad proteolytic specificity generally provides good sequence coverage, but 
the experimental set-up is not restricted to the use of pepsin, and could utilize other 
peptidases active under acidic pH. 
1.3.8 Studying protein dynamics in weakly structured regions of 
intrinsically disordered proteins 
This integrated experimental set-up was validated by application to a number of model 
systems, specifically highlighting the utility of sub-second HDX labeling to the 
examination of dynamics in weakly structured regions of protein. Utilizing a single 100 
ms HDX pulse Rob et al., 2012, were able to derive a crude secondary structure profile 
of ubiquitin by analyzing deuterium uptake in the pepsin-generated peptide fragments. 
Similarly, by fitting the kinetics of segment-specific HDX of cytochrome c, the relative 
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conformational flexibilities of loop regions were determined (Fig. 8). Loop flexibility was 
expressed as segment-averaged 'protection factors': a ratio of the calculated 'intrinsic' 
rate of exchange to the observed rate of exchange (which is attenuated by structure) 
(35). Experimentally-determined protection factors were in good agreement with 
previously derived or predicted properties of the specific loops and generally agreed 
with predictions based on the heme prosthetic group negatively impacting the dynamics 
of the regions it contacts, with those segments in closest contact with the heme group 
showing the least flexibility.  
On the millisecond timescale, backbone amide HDX in strongly hydrogen-bonded 
secondary structures is negligible. It was therefore possible to judge the extent to which 
the solution structure deviates from the reported (crystal or NMR) structure by 
comparing the observed level of exchange to the level expected based on the number 
of loop residues in the peptide.  
In yet another application of microfluidics-enabled 'bottom up' HDX, Rob et al., were 
able to study a large, rapid change in conformational flexibility associated with substrate 
binding in the large tetrameric enzyme, DAHP synthase (35). By comparing site-specific 
HDX kinetics of the free enzyme with the substrate-bound complex, the authors 
localized the changes in dynamics to a large region centered on the active site. The 
tetramer interface, however, remained largely unchanged in the presence and absence 
of substrate, and this was supported by the detection of primarily tetrameric DAHP 
synthase in the 'native' mass spectrum. Site-specific HDX analyses of DAHP synthase 
dynamics contributed an important mechanistic insight, suggesting that the residual 
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tetramer structure in the molten globule-like substrate-free form could be acting as a 
template for the development of structure upon substrate binding.  
One of the most exciting features of TRESI-MS/HDX is the ability to characterize 
residual structure in intrinsically disordered proteins (75). An example of this is a 
structural analysis of the neuronal Tau protein, which forms neurofibrillary tangles in 
Alzheimer’s disease. By examining the disordered regions of the Tau protein under 
native (non-amyloidogenic) and hyperphosphorylated (amyloidogenic) conditions, 
regions that undergo substantial structural rearrangement during the development of 
pathogenicity can be identified and characterized. Phosphorylation of the native Tau 
protein by GSK3β in vitro yields an amyloidogenic paired helical filament form (76), and 
subsequent TRESI-MS/HDX analysis of site-specific exchange rates between the two 
forms revealed striking differences in the rates of exchange, concentrated in the 
disordered regions and regions that fold into beta sheet structures in the native protein 
(manuscript in preparation). This experimental system can yield structural and kinetic 
insights that could greatly facilitate the development of new Tau aggregation inhibitors, 
as well as provide a platform for direct chemical library screens aimed at identifying new 
inhibitors.  
Site-specific HDX measurements on the millisecond timescale enabled by the 
microfluidics-coupled TRESI-MS are proving to be a versatile method for studying 
conformational dynamics in weakly structured protein regions and in IDPs. This 
approach is useful in an array of applications, from high-throughput predictions of 
secondary structure and dynamics to characterization of weak hydrogen bonding 
networks in flexible protein segments.
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Fig. 8 Analysis of Site-Specific HDX Rates in Weakly Structured Regions of Cytochrome 
c by Microfluidic Device-Enabled TRESI-MS. By fitting the kinetics of segment-specific 
HDX of cytochrome c, the relative conformational flexibilities of loop regions were 
determined. A) Representative kinetic plots of % deuterium exchange as a function of 
time for 9 peptide fragments of cytochrome c. The loop amide profiles based on the 
intrinsic rates are shown in black. The dashed line represents 100% exchange of loop 
amides. The measured profiles are colored by protection factor: blue (strong protection), 
green (moderate protection), orange (low protection), and red (very low protection). B) 
Structural representation of cytochrome c loop dynamics based on the time-resolved 
HDX data. Different loops are mapped onto the solution NMR structure of oxidized 
horse heart cytochrome c (1AKK) (77) and colored by protection factors as in (A). 
Structured regions represented by detected peptide fragments are colored light gray. 
Regions for which no peptides were observed are colored dark gray. Reprinted with 
permission from (35). © 2012 American Chemical Society. 
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1.3.9 Interrogating the Dynamics of Protein-Ligand Interactions by HDX 
MS 
The ability of HDX to probe rapid changes in the environment of backbone hydrogen 
amides with great sensitivity on the timescale of protein “breathing” motions makes it 
highly useful for probing the conformational dynamics and structural fluctuations in 
protein-protein and protein-ligand interactions. Probing of site-specific HDX, which is 
greatly facilitated by MS-based approaches, is ideally suited for sensing and resolving 
the perturbations in protein structure induced by ligand binding, both local and allosteric. 
Because ligand binding to a protein typically results in the exclusion of solvent 
molecules from the protein solvation shell and, in some cases, results in the formation 
of new hydrogen bonds between the protein and ligand, rapid decreases in deuterium 
uptake are often observed at the ligand-binding site. In the majority of cases, this 
clustering of decreases in deuterium uptake observed upon ligand binding can be 
interpreted to define the ligand-binding site and backbone regions interacting with the 
ligand. HDX has been applied to the study of protein-ligand interactions and associated 
dynamics to derive mechanistic insights in a variety of protein-ligand models, explaining 
ligand binding, catalysis, binding site preference, or allosteric regulation (78-81). Over 
the years, HDX has proven complimentary, if not indispensible, to other bioanalytical 
and structural biology techniques when interpreting protein-ligand interactions and the 
underlying parameters and mechanisms. One such example was the study of Bennett 
and co-workers, where they employed HDX MS in the characterization of a remote 
binding site for laulimalide, a new, non-taxane class of microtubule stabilizers, in the β-
tubulin protein (82). Following the unsuccessful attempts to resolve the laulimalide 
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binding site on β-tubulin by NMR and X-ray crystallography, likely owing to the highly 
dynamic and flexible nature of this protein-ligand pair, it was found by HDX MS to bind 
to a new site, not previously known to support ligand binding and located outside of the 
canonical paclitaxel-binding site. Using HDX, the authors were able to show that the 
laulimalide-binding site is unique in its ability to provide a hydrophobic surface for ligand 
stabilization that is considerably shallower and less tolerant to significant structure 
adaptation than other known ligand binding sites on β-tubulin, yet is exposed to the 
outside surface of the protein, making it difficult to interrogate by other structural 
techniques.  
Another good example of a successful application of HDX MS was a study by Zhang 
and co-workers, examining the binding of the Bcr-Abl inhibitor, GNF-5, a non-ATP 
inhibitor binding to the myristoyl pocket of the protein, and a close analog of GNF-2 
(83).  In this study, the combination of X-ray crystallography and solution NMR was 
sufficient to define the binding pocket of GNF-2 in Bcr-Abl, but these techniques failed 
to observe any allosteric changes that this inhibitor class could induce in the ATP-
binding pocket of the protein. The authors then applied HDX MS to probe the dynamic 
perturbations in Bcr-Abl structure induced by the binding of the GNF-5 analog to the 
myristoyl pocket of the protein, and observed clear, allosteric coupling between the 
myristoyl pocket and the distal ATP-binding site. This finding ultimately led the authors 
to uncover the mechanism for synergistic combination of GNF-5 with the ATP-binding 
site inhibitor, nilotinib. This and other studies highlight both the importance of probing 
protein conformational dynamics for the full understanding of the mechanistic steps 
occurring in protein-ligand interactions, and the utility of HDX MS to accomplish this.  
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1.4 Conclusion and Future Directions 
Coupling of ESI-MS to a microfluidic device that enables rapid mixing and provides an 
adjustable reaction chamber volume extends the reach of HDX analyses to weakly 
structured regions of proteins. The microfluidic device allows for continuous-flow 
experiments to be conducted, which greatly broadens the applicability of this 
methodology. In the study of enzyme kinetics, this device enables pre-steady state 
measurements to be conducted with ease, offers high selectivity for reaction 
intermediates, and permits the study of natural substrates and native enzyme-substrate 
intermediates. In the study of protein dynamics, microfluidics-enabled TRESI-MS/HDX 
is capable of characterizing conformational changes that occur rapidly and frequently – 
conditions that are largely inaccessible to conventional techniques – with a spatial 
resolution of 5 amino acid residues on average.   
Currently, site-specific HDX is limited to the analysis of a single structural species or an 
ensemble of species, which is the major limitation of this approach compared to the 
great deal of additional information it provides over global HDX experiments. This is 
because in order to measure site-specific HDX rates of multiple resident structural 
states, one has to be able to map the detected peptide fragments to the originating 
species. Proteolytic 'bottom-up' work-up of HDX-labelled proteins is thus intrinsically 
limited to a study of a single structural species (63). Non-ergodic gas phase 
fragmentation techniques such as ECD do not suffer from this limitation and are thus 
potentially highly applicable to the study of multiple resident structural states by time-
resolved, site-specific HDX (36,84). However, ECD has its own limitations, particularly 
low sensitivity and a size limitation (presently around 18kDa) (36).  
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Ultimately, TRESI-MS provides a powerful alternative for time-resolved studies of 
protein dynamics, revealing rapid, activity-linked conformational changes that occur in 
response to ligand binding, allosteric effects or post-translational modification. It is 
hoped that these new insights will translate into a much-improved understanding of 
protein function and the nature of pathogenic misfolding and aggregation in the cell. 
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Chapter 2  
 Epitope Mapping Using Microfluidics-Enabled 2
Millisecond Timescale Hydrogen-Deuterium 
Exchange 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter was submitted for publication as Resetca, D., and Wilson, D.J. 
“Epitope Mapping Using Microfluidics-Enabled Millisecond Timescale Hydrogen-
Deuterium Exchange”. 
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2.1 Summary 
A microfluidic device that integrates a full “bottom-up” workup for mass spectrometry-
based hydrogen-deuterium exchange (HDX) epitope mapping is described. The 
microfluidic device integrates a rapid mixer for millisecond timescale deuterium 
labelling, an acetic acid supply channel for exchange quenching, and a micro-digestion 
chamber filled with immobilized pepsin. The rapid mixer provides precise control over 
the deuterium labelling time. Direct coupling of the device to electrospray ionization 
mass spectrometry (ESI-MS) enables the workup cycle to be completed in less than 10 
seconds, providing a basis for future automation and applications requiring high sample 
throughput. Furthermore, microfluidic integration of the quenching channel minimizes 
the confounding effects of back-exchange, which can convolute readouts in 
conventional HDX set-ups. The glutathione-S-Transferase (GST) epitope for binding to 
its cofactor, glutathione (GSH), was evaluated as a proof of concept for binding-site 
mapping using this technique. Significant decreases in dynamics mapped exclusively to 
the GST active site epitopes that make direct contact with GSH via backbone hydrogen 
bonding. Capturing the evolution of dynamics in accommodating ligands is a highly 
predictive approach to characterizing ligand binding sites. 
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2.2 Introduction 
Hydrogen-deuterium exchange (HDX) Mass Spectrometry (MS), first introduced during 
the early 1990s for probing conformational changes in proteins (24,37), has recently 
experienced significant resurgence in interest paralleled by major technological 
advances. A major driver has been a move away from static representations of proteins 
towards dynamic ensembles that help better understand and predict biological 
processes and interactions (85,86). In addition to the relative ease of implementation, 
HDX offers substantial advantages over other methodologies, enabling the 
characterization of rapid conformational transitions and the interrogation of native 
structures in solution (87). 
Recently, microfluidic sample processing was introduced as a key enabling technology 
for HDX experiments (35,63,88). Microfluidics allows for controlled, short labelling 
pulses to be implemented reproducibly and for minimization of the confounding effects 
of back-exchange (in which the deuterium label is lost during subsequent sample 
handling steps). Integration of HDX workflows onto a microfluidic device greatly 
facilitates sample workup and extends HDX to site-specific measurements with up to a 
single amino acid resolution, ultimately allowing dynamic protein structures to be 
constructed. We have demonstrated a number of applications for a microfluidic device 
adapted for a ‘bottom-up’ HDX workflow ranging from interrogating enzyme active site 
dynamic (35), evaluating allosteric effects (88), or characterizing the flexibility/rigidity of 
native structural ensembles of proteins (89). Here we present the applications of this 
device to the investigation of protein-ligand interactions and identification of ligand 
binding sites. 
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To improve on conventional liquid chromatography-coupled HDX (LC-HDX) 
methodologies (90), which suffer from the inability to implement sub-second timescale 
deuterium labelling pulses and increased back-exchange, a microfluidic device was 
developed to conduct HDX experiments. This microfluidic device integrates a 
millisecond timescale capillary-based mixer (28), an HDX quenching channel, and a 
proteolytic digestion chamber for on-chip ‘bottom-up’ sample workup. Directly coupled 
to the electrospray ionization mass spectrometer (ESI-MS), this experimental set-up 
enables time-resolved HDX experiments (TRESI-MS/HDX) to be implemented in 
continuous mode.  
Two different approaches, ‘top-down’ and ‘bottom-up’ workups, have been developed 
for the site-specific analysis of HDX labelling of proteins. ‘Top-down’ approaches can be 
implemented by a variety of non-ergodic fragmentation methods that preserve 
deuterium label position, such as Electron Transfer Dissociation (ETD) (91) or Electron 
Capture Dissociation (ECD) (92). While these methods provide high spatial resolution 
(up to a single amino acid), they are currently limited to the analysis of HDX on small 
proteins (up to ~17kDa) (36). ‘Bottom-up’ workups use enzymatic proteolysis of the 
analyte protein, with acid proteases (most commonly pepsin) being the enzymes of 
choice to generate labelled protein fragments (93). Digestion is carried out a pH ~2.3, 
corresponding to the pH minimum of the HDX reaction, to ensure that exchange is 
quenched. ‘Bottom-up’ workups typically yield a spatial resolution of several amino 
acids (79). 
Site-specific deuterium incorporation into the protein backbone can be interpreted with 
respect to the solvent accessibility of backbone amides and the degree of their 
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involvement in hydrogen bonding (87). Lack of exchange (or lowering exchange rates) 
could reflect limited solvent accessibility or the presence of hydrogen-bonded amides. 
Since ligand binding can have a dramatic effect on both of these factors, HDX is highly 
useful in predicting ligand binding sites and the accompanying dynamic changes within 
the protein. Binding sites are typically identified as pronounced, localized decreases in 
exchange induced by solvent exclusion and/or formation of hydrogen bonds between 
the backbone amides and the ligand molecule. In some cases, decreased (or 
increased) exchange is observed far from the actual binding site, resulting from 
allosteric structural rearrangements associated with ligand binding. These allosteric 
effects can convolute binding site mapping somewhat, but ultimately structurally-
contiguous regions exhibiting pronounced changes in HDX (i.e. HDX hotspots) are a 
good indicator of ligand binding sites (94,95). 
In this study, we investigated the performance of the microfluidic device in the context of 
epitope mapping using the 26kDa isozyme of Glutathione-S-Transferase (GST) from 
Schistosoma japonicum (an infectious zoonotic parasite with a broad mammalian host 
range) (96). GST catalyzes the detoxification of a variety of xenobiotic substrates by 
conjugating them with a small, abundant tripeptide – a reduced (sulfhydryl) form of γ-
glutathione (GSH). GST is active as a dimer (97). It binds its substrates via the H-site of 
the catalytic domain in its C-terminal domain, while stably binding GSH as a cofactor in 
the G-site, a well-defined binding pocket, localized to its N-terminal domain (98). Here, 
we have interrogated the dynamics of apo-GST as well as that of GST stably 
complexed with the GSH cofactor as a model system for protein-ligand interactions. In 
the process, we have also evaluated the ability of time-resolved, site-specific HDX 
labelling to map protein-ligand interactions. 
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2.3 Experimental  
2.3.1 Materials 
Recombinant Glutathione-S-Transferase (>90% purity, GST from Schistosoma 
japonicum) produced in E.coli was purchased in lyophilized form from GenScript 
(Piscataway, NJ). Deuterium oxide (D2O – 99.99%), ammonium acetate (99.99%), 
acetic acid (99.7%), pepsin agarose beads, and reduced L-glutathione (γ-GSH) were 
purchased form Sigma Aldrich (St. Louis, MO). Dialysis cassettes (2.5kDa MWCO) 
were purchased from Fisher Scientific (Ottawa, ON). Metal capillaries (O.D. 355 µm, 
I.D. 177 µm and O.D. 400 µm, I.D. 254 µm) and PTFE tubing (O.D. 1/16”, I.D. 400 µm 
and O.D. 1/16”, I.D. 360 µm) were purchased from McMaster-CARR (Aurora, OH). 
Upchurch PEEK fittings 1/16” and PEEK MicroTEE were purchased from IDEX (Oak 
Harbor, WA). Poly-methyl-methacrylate (PMMA) blocks (8.9 cm × 3.8 cm × 0.6 cm) for 
production of the microfluidic device were purchased form Professional Plastics 
(Orchard Park, NY). Ultrapure water was generated in-house using a Millipore Milli-Q 
Advantage A10 system (Billerica, MA). 
2.3.2 Microfluidic Device Fabrication 
The microfluidic device for HDX workup was produced as described previously (30). 
The microfluidic device is illustrated in Fig. 9. Briefly, standard PMMA block (8.9 cm × 
3.8 cm × 0.6 cm) was laser-ablated to incorporate two input channels for introduction of 
reactants, a proteolytic digestion chamber and a third output channel using the 
VersaLaser™ engraver (Universal Laser, Scottsdale, AZ). The first channel was utilized 
for embedding the rapid-mixing device (28) (for D2O labelling). The second channel 
was used for the supply of quenching solution (5% acetic acid pH 2.4). A proteolytic-
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digestion chamber for pepsin-agarose beads (average diameter 20-50 µm) was edged 
in a rectangular shape (30 mm × 5 mm × 0.05 mm). The output channel feeds directly 
into the MS. A blank PMMA block was used as a cover to seal the device, lined with a 
silicon-rubber gasket for liquid-tight seal. A custom-build pressure-clamp was used to 
secure the device seal (LAC Machine & Tooling Limited, Toronto, ON). Metal capillaries 
were melted into the etched PMMA chip in order to connect the supply syringes to the 
device and provide an outlet for direct coupling to MS. Reactants were supplied into the 
device with gas-tight Harvard syringes through PTFE tubing using automated infusion 
pumps (Harvard, Holliston, MA). 
2.3.3 HDX Measurements 
HDX experiments were carried out in triplicate on GST alone or GST pre-incubated with 
GSH. Reconstituted GST protein was dialyzed overnight into 100 mM ammonium 
acetate buffer (pH 7.5). Lyophilized reduced GSH was reconstituted as a 10mM solution 
in deionized water, and was pre-incubated with GST (80 µM) for 2 hours on ice prior to 
HDX experiments (final GSH concentration of 400 µM, 1:5 molar ratio). The microfluidic 
device was directly coupled to the front-end of a modified QStar Elite hybrid quadrupole 
time-of-flight (Q-TOF) mass spectrometer (AB Sciex, Framingham, MA). GST solutions 
were infused through a polyamide-coated glass capillary into the rapid mixing device at 
a flow rate of 1 µL min-1. Deuterium was supplied through outer metal capillary at a flow 
rate of 3 µL min-1. The resulting maximum labelling was 75%. Deuteration pulse length 
was controlled by the withdrawal of the inner capillary and was calculated by measuring 
the position of the inner capillary in reference to the outer capillary of the rapid mixing 
device. 5% acetic acid solution for quenching was supplied through the secondary 
channel at a flow rate of 15 µL min-1. 
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2.3.4 Mass Spectrometry 
ESI-MS HDX experiments were performed on a QStar Elite Q-TOF instrument. A 
bypass switch was introduced to simulate the presence of a commercial source. 
Acquisition was carried out in a positive ion mode, with an electrospray voltage of +4700 
V to +4900 V, 60 V declustering potential and 250 V focusing potential. Spectra were 
acquired over the range of 300-1600 m/z with a scanning rate of 1 s-1.  
2.3.5 Analysis 
All spectra analyses were performed on the mMass software, version 5.5 (99). 
Deuterium incorporation was computed utilizing an in-house developed software. HDX 
data was fit using single exponential non-linear regression and normalized in SigmaPlot 
(Systat Software, San Jose, CA). All protein structures were rendered using PyMOL 
(The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.). 
2.4 Results and Discussion 
2.4.1 Microfluidic HDX-MS Device for Characterization of Protein 
Dynamics 
Millisecond-timescale HDX kinetics of protein-ligand complexation were interrogated 
using TRESI-MS/HDX on the microfluidic device shown in Fig. 9. The device comprises 
a capillary-based rapid-mixer and a quenching channel supplying acetic acid, both 
embedded into the PMMA chip, as well as etched channels for reagent supply that 
converge into an etched proteolytic digestion chamber. The digestion chamber is filled 
with pepsin that has been immobilized onto agarose beads. This integrated, continuous-
flow set-up is directly coupled to the electrospray emitter and permits the complete 
‘bottom-up’ workup to be performed on the device. The capabilities of the device for 
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characterizing ligand binding were evaluated via a well-studied interaction between GST 
with its natural cofactor γ-GSH. GSH complexes with GST in a defined binding pocket at 
the active site (Kd of 3.5x10-5M) (100), forming a complex that is stable in the absence 
of substrates. With GSH acting as a cofactor, this comprises an ideal system for the 
investigation of a natural enzyme-substrate type of protein-ligand binding interaction as 
it eliminates the need for substrate analogues or synthetic inhibitors to stabilize the 
protein-ligand complex. 
The rapid mixer occupies one of the channels of the device and consists of an inner 
polyamide-glass capillary that has been sealed, notched 2 mm away from the plug, and 
inserted into a metal outer capillary (Fig. 9). A three-way union permits the integration of 
the inner capillary into the outer capillary, while connecting the outer capillary to the 
PTFE tubing that supplies the deuterated water. In the current set-up, GST alone, or 
pre-incubated with GSH, was flowed into the rapid-mixer through the inner capillary, 
entering through the notch into the mixing chamber (the volume between the inner and 
outer capillaries around the notch region), where it was exposed to the deuterated water 
supplied through the outer capillary. After mixing, the solution was passed into a 
reaction region whose volume was controlled by the position of the inner capillary within 
the outer capillary, resulting in variable reaction times. 
HDX was rapidly quenched with the supply of 5% acetic acid through a separate 
channel, connecting downstream of the mixing chamber. It was previously determined 
that this quenching step lowers the pH of the reaction to approximately 2.6, which, 
combined with an exceedingly short (~4 s) residence time in the device, virtually 
prevents back-exchange (35). The protein unfolds during this step, facilitating 
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proteolysis by pepsin (whose activity maximum is at pH 2) in the subsequent chamber. 
Acidified GST was digested by pepsin immobilized onto agarose beads that fill the 
protein digestion chamber (Fig. 9). The resulting digest was continuously electrosprayed 
directly into the mass spectrometer for analysis. 
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Fig. 9 Microfluidic Device for Millisecond Timescale Continuous Labelling HDX 
Integrating Complete ‘Bottom-up’ Workup. The device comprises a capillary-based 
rapid-mixer and a quenching channel supplying acetic acid, both embedded into the 
PMMA chip. The chip harbors etched channels for reagent supply that converge into an 
etched proteolytic digestion chamber, which is filled with pepsin agarose beads. The 
rapid mixer occupies the central input channel of the device and consists of an inner 
polyamide-glass capillary that has been sealed, notched 2 mm away from the plug, and 
inserted into a metal outer capillary. A three-way union permits the integration of the 
inner capillary into the outer capillary, and connects the outer capillary to the PTFE 
tubing that supplies the deuterated water. The protein solution enters the device through 
the inner capillary of the mixer. Following the deuterium labeling pulse, the solution 
mixes with the acetic acid quencher, and then passes through the proteolytic digestion 
chamber. The resulting peptide mixture is injected directly into MS for analysis. 
Protein + Ligand
D2O
5% Acetic Acid
Rapid Mixing
Proteolytic Digestion
ESI
HDX Quenching
Capillary Withdrawal 
Adjusts Mixing Time
Hydrogen
Deuterium
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Individual peptides were identified from raw MS spectra and theoretical and actual 
isotopic distributions were calculated for each observed fragment (101). Representative 
spectra of peptides mapping to the GSH binding site of GST are shown in Fig. 10A, 
demonstrating significant changes in HDX as a result of GSH complexation. Fig. 10A 
shows non-deuterated GST spectra, as well as spectra of GST, with or without 
complexed GSH, treated with a D2O labelling pulse of 2.02 s. Isotopic distributions for 
each labelling time-point were computed for all observed peptic peptides to derive 
percent deuterium uptake. The complete HDX kinetics are depicted for representative 
peptides in Fig. 10B, demonstrating a clear decrease in deuterium uptake by the holo-
GST-GSH complex as opposed to the apoenzyme. Table 1 lists the percent deuterium 
uptake calculated for all off the peptic peptides identified in the study, for the apo-GST 
and GST-GSH complex. Fig. 11 is a heat map representation of deuterium uptake of the 
GST apo- (Fig. 11A) and holoenzyme (Fig. 11B), as derived from triplicate HDX 
measurements, modelled onto the crystal structure of the protein (1GTA for apoenzyme 
and 1M9A for holoenzyme, where GST was docked in place of a GSH analogue) (102). 
Comparison of deuterium uptake between the structures reveals that significant HDX 
changes are confined to the active site of the protein. 
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Fig. 10 Analysis of Site-Specific HDX in GST-GSH Ligand Binding. A) Representative 
spectra of peptides mapping to the GSH binding site of GST for non-deuterated GST 
(top row), GST labeled by a 2.02 s HDX pulse (middle row), and GST complexed with 
GSH labeled by a 2.02 s HDX pulse (bottom row). Raw spectra depict the observed 
shifts in isotopic distribution following HDX. Percent deuterium uptake is shown for each 
spectrum. B) Normalized HDX kinetic plots of representative peptides mapping to the 
GSH binding site of GST derived for the GST apoenzyme (closed circles) or GST-GSH 
holoenzyme (open squares). 
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Table 1. Site-Specific Deuterium Uptake by GST and GST-GSH Complex. Calculated 
percent deuterium uptake is shown for each peptic peptide that was identified in the 
analysis of GST and GST-GSH complex (each experiment was repeated three times; 
corresponding SEM is shown).
Peptic	  Peptide Sequence Observed	  Amplitude	  
(GST)
Std.	  Error Observed	  Amplitude	  
(1:5	  GST:GSH)
Std.	  Error
MSPILGY/(W) 1-­‐7 67.9 0.9 71.2 4.4
(Y)/WKIKGLVQPTRL/(L) 8-­‐19 83.1 2.3 83.8 5.7
(L)/VQPTRLL/(L) 14-­‐20 89.6 2.4 96.8 6.7
(E)/YLEE/(K) 23-­‐26 99.9 2.7 95.2 6.7
(K)WRNKKFELG(L) 41-­‐49 88.1 1.5 81.2 4.0
(F)/ELGLE/(F) 47-­‐51 62.1 2.6 58.4 2.9
(F)/PNLPYY/(I) 53-­‐58 42.2 1.1 27.5 1.2
(Y)/YIDGDVK(L) 58-­‐64 81.7 5.9 79.7 5.8
(F)/PNLPYYIDG(D) 53-­‐61 74.2 1.3 59.2 4.2
(Y)/IDGDVK(L) 59-­‐64 51.1 1.2 49.3 2.8
(G)DVKLTQSM(A) 62-­‐69 84.0 2.9 68.1 5.0
(A)/IIRY/(I) 71-­‐74 32.8 2.3 31.9 3.5
(K)ERAEIS(M) 88-­‐93 84.3 4.4 84.6 3.1
(R)AEISMLE/(G) 90-­‐96 73.3 2.8 70.3 5.2
(L)/EGAVL/(D) 96-­‐100 65.0 1.8 63.8 3.9
(Y)/GVSRIAYS(K) 105-­‐112 94.3 2.4 96.7 5.5
(D)FETL/(K) 115-­‐118 81.9 1.7 83.2 4.7
(V)DFLS(K) 121-­‐124 77.4 2.9 78.0 5.5
(D)FLSKLPE/(M) 122-­‐128 69.1 3.1 67.2 5.0
LSKLPEM/(L) 123-­‐129 86.4 0.9 78.1 2.1
(F)/EDRLC(H) 134-­‐138 87.0 3.6 91.7 6.1
(L)/NGDHVTHPDF/(M) 144-­‐153 84.2 2.8 88.8 6.5
(Y)/MDPMCLDAFPKLVCF/(K) 165-­‐179 70.0 1.1 68.8 7.1
(F)/KKRIEAIPQIDKY/(L) 180-­‐192 56.2 1.6 60.5 3.7
(Y)/IAWPLQG(W) 199-­‐205 68.8 1.5 75.3 2.7
(G)WQATFGGGDHPPKSDL/(V) 206-­‐221 68.5 1.4 66.2 3.9
(L)/VPRGSPGIHRD 222-­‐232 79.5 5.4 73.8 4.0
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Fig. 11 Average Deuterium Uptake in Mapped onto the Crystal Structure of A) GST 
apoenzyme (PDB ID#1GTA) and B) GST complexed with GSH (modelled with GSH 
based on PDB ID#1M9A). GSH molecule is depicted as a stick representation coloured 
by element. Low (blue shading) represents 0-20% deuterium uptake, followed by green 
(20-40%), yellow (40-60%), orange (60-80%), and then high (red shading) representing 
80-100% deuterium uptake. 
 
Low                                                                           High 
a) b)  
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2.4.2 Device Performance 
A number of criteria are considered in assessing the performance of a microfluidic 
device for site-specific HDX experiments. Some of the key criteria include rapid 
incorporation of the deuterium label, precise control over the labelling/quenching times, 
accessible timescale for HDX labelling, rapid workup, and protein sequence coverage. 
The mixing chamber volume of the capillary-based mixer is between approximately 8 
and 12 nL, depending on the diameter of the capillaries used, enabling an effective 
mixing to be achieved in as little as 5 ms (28,35,63,88). The deuterium labelling time is 
controlled by the positioning of the inner capillary, which could be done with a precision 
of at least 0.5 mm, translating in the current system, with a total flow rate of 4 µL min-1, 
into 185 ms increments. In the present study, D2O labelling pulses ranged from 179 ms 
and up to 7.56 s, effectively capturing HDX pre-equilibrium kinetics on a broad 
millisecond to second range (Fig. 10B). In contrast, the accessible timescale of the 
typical LC-HDX setup extends down to a minimum labelling time of 10 s (103). 
Millisecond pulses enabled by the HDX microfluidic device are particularly useful in 
interrogating the rapid evolution of protein dynamics of weakly-structured protein 
regions (35), inaccessible to other HDX-based techniques. Residence time of the 
protein in the proteolytic chamber is estimated at only approximately 4 s. This enables 
sufficient digestion to occur while further minimizing contribution from back-exchange 
that plagues conventional LC-HDX methods with post-labelling workup times that are at 
least an order of magnitude longer (104). 
Another important performance indicator of HDX experiments is sequence coverage, 
which is influenced mainly by digestion efficiency. In a ‘bottom-up’ workup, the 
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backbone amides of the first two amino acid of each peptic peptide will back-exchange 
rapidly and would always be missed from the analyses, reducing sequence coverage 
(105). However, pepsin’s tendency to miss cleavage sites results in the generation of 
overlapping peptides, compensating for this (79). Thus, sequence coverage is highly 
dependent on the amino acid sequence, secondary and tertiary structure, and residence 
(digestion) time on the chip, generally yielding sequence coverage of anywhere 
between 50% and 98% (29). In the current GST system, we achieved sequence 
coverage of 68% (based on 30 peptides analyzed, Fig. 12) and an average spatial 
resolution of 5.6 amino acids. Most of the observed GST peptic peptides were derived 
from the low-structured regions of the protein (Fig. 11). Using a cut-predictor 
PeptideMass tool on the ExPASy proteomic server (Swiss Institute of Bioinformatics, 
Basel, Switzerland) (106), one can predict expected cleavage sites, and the resulting 
peptides. Such an analysis of the GST sequence revealed that, in order to generate 
peptic peptides observed in the current experiments, an average of 1-2 missed 
cleavage events were required for most peptides. However, analysis of the regions for 
which we did not obtain sequence coverage reveals that more frequent missed 
cleavages (3 or more on average) would have been required to generate useful 
coverage. Furthermore, the majority of sequence coverage encompassed low-
structured regions of GST, suggesting that the protein could have retained a degree of 
residual secondary/tertiary structure after acidification.  
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Fig. 12 Primary Protein Sequence and Secondary Structure Assignment (based on the 
Dictionary of Protein Secondary Structure (DSSP) Assignment (107))) of GST (PDB ID: 
1GTA). Peptic peptides resolved and analyzed in the HDX experiments are indicated 
above the primary sequence. Total GST sequence coverage is 68%.
1 10             20            30             40             50          60
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYID
61            70             80            90             100            110          120
GDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKV
121           130            140           150            160            170         180
DFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFK
181           190            200           210            220            230
KRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSPGIHRD
no	  2° structure α-­‐helix β-­‐strand
turnβ-­‐bridge peptic	  peptide
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The GST sequence coverage obtained was sufficient to observe peptic fragments of 
major interest, corresponding to the GSH binding site at the N-terminus of the protein 
(Fig. 13A). Peptides from this region exhibit the most pronounced decreases in HDX 
upon complexation of GST with GSH, as apparent from the analysis of fold deuterium 
uptake changes throughout the protein sequence (Fig. 13B). While the GSH binding 
pocket is known in this case, these results show unambiguously that time-resolved HDX 
is a promising tool for de novo identification of ligand binding sites. 
2.4.3 Evolution of GST Dynamics upon Complexation with GSH 
In time-resolved HDX-based protein dynamics experiments, the degree of deuterium 
incorporation into the backbone amides of a peptic fragment provides information on the 
extent of solvent accessibility and/or hydrogen bonding that this region experiences 
within the population ensemble of the native protein species in solution. This information 
can ultimately be interpreted to document changes in secondary structure, 
rearrangement of the hydrogen bonding network, or the binding of ligands, where 
backbone amides are directly involved. With the application of our microfluidic device, 
we were able to generate a dynamic structure of GST that reflects the rearrangements 
of the hydrogen bonding network of the GST backbone to accommodate GSH binding 
to the active site. 
58 
 
 
Fig. 13 Fold Change in Deuterium Uptake Between GST apoenzyme and GST 
Complexed with GSH. A) Fold change in deuterium uptake mapped onto the GST 
amino acid sequence as compiled from the detected peptic fragments. B) Hotspots of 
differential deuterium uptake (blue shading) mapped onto the crystal structure of GST 
complexed with GSH (modelled with GSH based on PDB ID: 1M9A). Hydrogen bonds 
forming between the backbone amides of the highlighted peptides and GSH are 
indicated by red arrows. Backbone amide of Leu55 in peptides 53-58 & 53-61 forms a 
hydrogen bond to the cysteinyl carbonyl of GSH. Backbone amide of Ser68 in peptide 
62-69 forms a hydrogen bond to the γ-glutamyl carboxylate of GSH. 
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The three residues of γ-GSH make a specific contact with GST primarily through 
hydrogen bonding either to the side-chain or backbone (102). Residues Trp41 and 
Lys45 of GST stabilize the glycyl carboxylate group of GSH by side-chain hydrogen 
bonding, while glycyl amino group forms a hydrogen bond with Asn54. Trp8 forms a 
side-chain hydrogen bond with the cysteinyl carbonyl of GSH, while the amino portion of 
the GSH cysteinyl region forms hydrogen bonds with backbone of Asn54 and Leu55 
residues. Amino group of the γ-glutamyl of GSH also forms hydrogen bonds with the 
side-chains of Asp101 and Gln67. Ser68 forms a hydrogen bond with the carboxylate 
group of the γ-glutamyl of GSH to both its backbone and side-chain. Thus, Asn54, 
Leu55, and Ser68 of GST all form hydrogen bonds with GSH via their backbone amides 
and are residues of interest in investigating GSH binding by GST by HDX labelling.  
Newly created hydrogen bonds are indicated in the GST-GSH complex in Fig. 13B (red 
arrows), consistent with a significant decrease in deuterium uptake in peptides spanning 
residues 53-58/53-61 and 62-69 (coloured blue), mapping to the GSH binding site. 
Backbone amide of Leu55 in peptides 53-58/53-61 and Ser68 in peptide 62-69 form 
hydrogen bonds to the cysteinyl carbonyl and γ-glutamyl carboxylate of GSH, 
respectively. Independently detected and analyzed overlapping peptides 53-58 and 53-
61, both containing Leu55 that hydrogen bonds with GSH, demonstrate equivalent 
decrease in magnitude of deuterium uptake (by approximately 11%), underscoring the 
high reproducibility of the microfluidic device and the HDX technique. We do not 
observe Asn54, since the backbone amide of this residue (second amino acid in 
peptides 53-58 and 53-61) back-exchanges rapidly. To get around the coverage 
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sequence limitation of the HDX experiments, alternative proteases could be employed 
in parallel analyses, such as nepenthesin (108). 
In the current model complex, the dynamics of the highly specific binding of the GSH 
cofactor by the GST G-site are expected to be dominated by a relatively rigid lock-and-
key mechanism (unlike the binding of GST substrates to the hydrophobic H-site, which 
enjoys considerable substrate flexibility) (109). This is consistent with the observation of 
minute (largely negligible) changes in deuterium uptake outside the binding pocket 
between the GST apoenzyme and GST-GSH complex (Fig. 13A), indicating a lack of 
allosteric transitions in the dynamics accompanying GSH binding. The active dimer of 
the mu-class GST enzymes does not normally experience catalytic cooperativity 
between the active sites of the two subunits (98,110). This is also consistent with the 
lack of dramatic HDX changes throughout the protein globally, and the dimer interface 
in particular (peptides 96-100, 105-112). 
2.5 Conclusions 
In this work, we describe a new application of our microfluidic device for millisecond-
timescale continuous labelling HDX. We conducted site-specific HDX experiments to 
interrogate the dynamics of protein-ligand interactions and identify ligand binding site 
using a model system of GST complexed with its cofactor, GSH. The microfluidic device 
yielded a broad range of precise HDX labelling pulses and reproducible site-specific 
deuterium uptake measurements. Comparison of the differential deuterium uptake 
between the GST apoenzyme and the GSH-complexed protein successfully revealed an 
HDX hotspot that mapped to the GSH binding site. This data represents the first 
practical implementation of the microfluidic HDX device for rapid identification of a 
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ligand binding site in a protein. This fully integrated device reduces the entire HDX 
workup time down to less than 10 s per labelling cycle, enabling future automation for 
applications requiring high sample throughput, such as a compound library screening 
assay (111). We now extend the already broad array of applications of this microfluidic 
HDX device and establish it as a powerful tool for the study of protein-ligand complexes 
and mapping of ligand binding sites. 
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Chapter 3  
 Allosteric Changes in STAT3 Induced by 3
Complexation with Pharmacological Inhibitors of SH2 
Domain Dimerization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter was submitted for publication as Resetca, D., Haftchenary, S., 
Gunning, P.T., and Wilson, D.J. “Allosteric Changes in STAT3 Induced by Complexation 
with Pharmacological Inhibitors of SH2 Domain Dimerization”. 
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3.1 Summary 
The activity of the transcription factor STAT3 is dysregulated in a number of 
hematological and solid malignancies. Development of pharmacological STAT3 SH2 
domain inhibitors holds great promise for cancer therapy, and a novel class of salicylic 
acid-based STAT3 dimerization inhibitors has been recently developed that includes 
orally-bioavailable drug candidates. The compounds SF-1-066 and BP-1-102 are 
predicted to bind to the STAT3 SH2 domain. However, given the highly unstructured 
and dynamic nature of the SH2 domain, experimental confirmation of this prediction was 
elusive. We have interrogated the protein-ligand interaction of STAT3 with these small-
molecule inhibitors by means of time-resolved hydrogen-deuterium exchange mass 
spectrometry (TRESI-MS/HDX). Analysis of site-specific evolution of deuterium uptake 
induced by the complexation of STAT3 with SF-1-066 or BP-1-102 under physiological 
conditions enabled the mapping of the in silico-predicted inhibitor-binding site to the 
STAT3 SH2 domain. The binding of both inhibitors to the SH2 domain resulted in 
significant local and global decreases in dynamics, consistent with solvent exclusion at 
the inhibitor binding site and increased rigidity of the inhibitor-complexed SH2 domain. 
Interestingly, inhibitor binding revealed hotspots of allosteric perturbations outside of the 
SH2 domain, manifesting mainly as increased deuterium uptake, in regions of STAT3 
protein important for DNA binding and nuclear localization of the protein. Understanding 
how pharmacological inhibitors of STAT3 dimerization interact with its SH2 domain and 
affect the dynamics of the entire protein is critical to the development of next-generation 
STAT3 inhibitors. 
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3.2 Introduction 
Signal Transducer and Activator of Transcription 3 (STAT3), an SH2 domain-containing 
protein (MW 88kDa), mediates intracellular signaling downstream of a number of 
cytokine and growth factor receptors and is involved in regulating cell proliferation, 
survival, differentiation, angiogenesis, cell migration, and inflammatory signaling (112). 
Dysregulated STAT3 activity promotes the progression of a multitude of hematological 
and solid malignancies (113). STAT3 is a transcription factor, whose activation is 
modulated by tyrosine phosphorylation. Activating phosphorylation at Tyr705 drives 
STAT3 homo-dimerization or hetero-dimerization with other STAT family members 
mediated by its Src Homology 2 (SH2) domain (114), which binds the phosphotyrosine 
peptide with nanomolar affinity (115). Inhibition of SH2 domain function is thus a robust 
strategy to antagonize its biological activity (116).  
The SH2 domain is a structurally conserved feature of many intracellular signaling 
transducers and is capable of recognizing and binding to phosphorylated tyrosine 
residues presented in the context of specific protein sequences (117). Comprising 
minimal secondary structure, the SH2 domain and the phosphopeptide-binding interface 
are highly unstructured and dynamic (118) – a property that makes the development of 
small molecule inhibitors targeted at this important domain class a challenge. Gunning 
and co-workers have recently developed a number of pharmacological, orally-
bioavailable inhibitors of STAT3 based on the salicylic acid pharmacophore through a 
series of QSAR studies (119,120). Two such inhibitors, SF-1-066 and BP-1-102, 
demonstrate an IC50 of 35 µM and 19.7 µM, respectively, for the inhibition of STAT3 
DNA binding activity in vitro, and inhibit STAT3 dimerization (121). Additionally, BP-1-
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102 has demonstrated potent anti-tumor effects in vivo in human breast and lung cancer 
xenograft studies in mice (119). In silico docking studies identified a putative binding site 
for the two inhibitors comprising all three phosphopeptide-binding sub-pockets of the 
SH2 domain (121). However, little experimental evidence exists corroborating that the 
putative binding site of SF-1-066 and BP-1-102 is indeed in the SH2 domain and the 
mechanism of action of these molecules is not yet fully understood.  
While a number of X-ray crystal structures of STAT3 are available (122,123), including 
that of the phosphorylated STAT3 dimer (124), derivation of X-ray crystal structures of 
STAT3 complexed with SF-1-066 and BP-1-102 is laborious and is expected to be 
limited in utility to binding site identification. Unlike these static images, dynamic 
representations of protein structures can offer mechanistic insights into biological 
processes and interactions by depicting the time-evolution of protein conformational 
ensembles (87). Hydrogen-deuterium exchange (HDX) mass spectrometry (MS), when 
coupled with microfluidic sample processing, enables the interrogation of protein 
dynamics of the native protein structures in solution, permitting the in situ observation of 
enzyme-catalyzed reactions (63) and protein-ligand interactions (88). HDX, 
implemented on a microfluidic device for rapid mixing, quenching and proteolytic 
digestion of the protein analyte, offers substantial advantages over other techniques, 
including: easy implementation, unlimited protein analyte size, timescales compatible 
with protein breathing motions, and site-specific resolution of up to few amino acids 
(35).  
We have extended the application of time-resolved MS HDX (TRESI-MS/HDX) to the 
study of protein-ligand interactions involving the highly unstructured SH2 ligand-binding 
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domain in the context of the near full-length STAT3 protein. In the present work, TRESI-
MS/HDX was applied to (i) experimentally identify the STAT3 binding site of the salicylic 
acid-based inhibitors, SF-1-066 and BP-1-102, and (ii) probe the changes in protein 
dynamics induced in STAT3 upon complexation with these inhibitors. 
3.3 Experimental Procedures 
3.3.1 Reagents 
SF-1-066 and BP-1-102 were synthesized as described previously (121) and were 
dissolved in DMSO. Deuterium oxide (D2O – 99.99%), ammonium acetate (99.99%), 
acetic acid (99.7%), and pepsin agarose beads were purchased form Sigma Aldrich (St. 
Louis, MO). Dialysis cassettes (30kDa MWCO) were purchased from Fisher Scientific 
(Ottawa, ON). Vivaspin 20 (30kDa MWCO) columns were purchased from GE 
Healthcare (Baie d’Urfe, QC). 
3.3.2 Cloning, Expression and Purification of the STAT3 Fusion Protein 
A plasmid containing mouse His-tagged STAT3 was provided by Dr. Rob C. Laister 
(Toronto, ON). STAT3, residues 127-688 (100% sequence identity on the protein level 
between mouse and human), was excised with NdeI and BamHI and subcloned directly 
into the pMAL-c5X plasmid digested with the same restriction enzymes to generate an 
N-terminal MBP (Maltose-Binding Protein)-tagged fusion of STAT3. The resulting 
pMAL-c5X- STAT3 plasmid was transformed into E. coli BL21(DE3) for inducible 
expression. The resulting MBP-human STAT3 fusion was purified on the Amylose Resin 
affinity-chromatography resin (New England Biolabs Inc. Ipswich, MA). Purified STAT3 
was further concentrated to 80 µM and buffer exchanged into 100 mM ammonium 
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acetate buffer pH 7.4 using the Vivaspin 20 filtration column (GE Healthcare). Purity 
was confirmed by SDS-PAGE and absorbance at 280 nm to be above 95%. 
3.3.3 Microfluidic Device Construction 
Microfluidic device for HDX workup was constructed as described previously (35). 
Briefly, a standard PMMA block (8.9 cm × 3.8 cm × 0.6 cm) was laser-ablated to 
incorporate two input channels for introduction of reactants, a proteolytic digestion 
chamber and a third output channel using the VersaLaser engraver (Universal Laser, 
Scottsdale, AZ). The rapid-mixing device, described previously (28), was embedded into 
the first input channel to supply the protein solution and D2O for labelling. The second 
channel supplied the quenching solution (5% acetic acid pH 2.4). A proteolytic-digestion 
chamber was edged in a rectangular shape (30 mm × 5 mm × 0.05 mm) onto the device 
and filled with pepsin-agarose beads (average diameter 20-50 µm). The output channel 
fed directly into the MS. A blank PMMA block was used as a cover to seal the device, 
lined with a silicon-rubber gasket for liquid-tight seal. A custom-build pressure-clamp 
was used to secure the device seal (LAC Machine & Tooling Limited, Toronto, ON). 
Metal capillaries were melted into the etched PMMA chip in order to connect automated 
supply syringes to the device and provide an outlet for direct coupling to the MS. 
Reactants were supplied into the device with gas-tight Hamilton syringes through PTFE 
tubing using automated infusion pumps (Harvard, Holliston, MA). 
3.3.4 Hydrogen-Deuterium Exchange Mass Spectrometry 
HDX experiments were carried out in triplicate with an 80 µM solution of STAT3 pre-
incubated with 400 µM SF-1-066, 400 µM BP-1-102, or a DMSO only control for 2 hours 
on ice. The microfluidic device was directly coupled to the front-end of a modified QStar 
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Elite hybrid quadrupole time-of-flight (Q-TOF) mass spectrometer (AB Sciex, 
Framingham, MA). A bypass switch was introduced to simulate the presence of a 
commercial ESI source. STAT3 solutions were infused through a polyamide-coated 
glass capillary into the rapid mixing device at a flow rate of 1 µL min-1. Deuterium was 
supplied through the outer metal capillary at a flow rate of 3 µL min-1. The resulting 
maximum deuteration was 75%. Deuteration pulse length was controlled by the 
withdrawal of the inner capillary and was calculated by measuring the position of the 
inner capillary in reference to the outer capillary in the rapid mixing device. Pulse 
lengths ranged from 179 ms and up to 7.56 s. 5% acetic acid solution was supplied to 
quench the exchange through the second input channel at a flow rate of 15 µL min-1. 
ESI-MS acquisition was carried out in a positive ion mode, with an electrospray voltage 
of +4700 V to +4900 V, 60 V declustering potential and 250 V focusing potential. 
Spectra were acquired over the range of 300-1600 m/z with a scanning rate of 1 s-1. 
3.3.5 In Silico Docking of SF-1-066 and BP-1-102 to STAT3 SH2 
Domain Crystal Structure 
Structures of SF-1-066 and BP-1-102 were docked into the STAT3 SH2 domain 
structure (derived from PDB ID: 1BG1) using the GOLD software package (Cambridge 
Crystallographic Data Centre, Cambridge, UK) as described previously (120). 
3.3.6 Data and Statistical Analyses 
All MS spectra analyses were performed on the mMass software, version 5.5 (99). 
Peptic peptide identification was performed using a FindPept tool on the ExPASy 
proteomic server (Swiss Institute of Bioinformatics, Basel, Switzerland) and confirmed 
by CID where needed. Deuterium incorporation was computed using software for 
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isotopic distribution analysis developed in-house. HDX data was fitted using single 
exponential non-linear regression and normalized in SigmaPlot (Systat Software, San 
Jose, CA). Protein structures were rendered using PyMOL (The PyMOL Molecular 
Graphics System, Version 1.5.0.4 Schrödinger, LLC.). 
3.4 Results 
3.4.1 TRESI-MS Analyses of STAT3 and STAT3-Inhibitor Complexes 
STAT3 was pre-incubated with 400 µM or a 1:5 molar excess of SF-1-066 or BP-1-102 
inhibitors (inhibitor structures are shown in Fig. 14A and B). This concentration was 
expected to have saturated STAT3, given the experimentally determined Kd for SF-1-
066 and BP-1-102 of 2.74 µM and 504 nM, respectively (119,125). Fig. 14C shows how 
SF-1-066 (yellow) and BP-1-102 (green) are predicted to bind to the SH2 domain of 
STAT3, based on in silico docking simulations. In these models, residues Lys591, 
Arg609, Ser611, and Ser613 are predicted to make direct contact with the pTyr-mimetic 
portion of the scaffold, ortho-hydroxybenzoic acid, via hydrogen bonding and 
electrostatic interactions in the pTyr-binding sub-pocket. The hydrophobic cyclohexyl-
benzyl moiety is predicted to form van der Waals’ contacts with the distal, hydrophobic 
sub-pocket of the SH2 domain, lined by residues Trp623, Val637 and Ile659. The 
Sulfonamide-substituted group of the inhibitors is predicted to access an additional sub-
pocket of the SH2 domain and are predicted to interact with Lys591, Glu594, Arg595 
and Ile634 (119,121).   
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Fig. 14 Structure of the Salicylic Acid-Based Inhibitors, A) SF-1-066 and B) BP-1-102, 
are depicted. C) Representation of the results of in silico docking of SF-1066 (yellow) 
and BP-1-102 (green) inhibitors to the phosphotyrosine peptide-binding pocket of the 
STAT3 SH2 domain. 
BP-­‐1-­‐102SF-­‐1-­‐066
A B C 
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Fig. 15 Primary Protein Sequence and Secondary Structure Assignment (based on the 
Dictionary of Protein Secondary Structure (DSSP) assignment (107)) of the human 
STAT3 (PDB ID: 1BG1) segment of the MBP-STAT3 fusion protein. Peptic peptide 
resolved and analyzed in the HDX experiments are indicated above the primary 
sequence. Total STAT3 sequence coverage is 71%.
127 130            140            150           160            170            180         190
GQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSV
196 200            210       220            230            240            250         260
TRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLEN
266 270            280            290            300           310            320          330
WITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDR
336 340            350            360            370           380            390          400
PLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLS
406  410            420            430            440           450            460          470
AEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWA
476 480            490            500            510           520            530          540
SILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQIT
546  550            560            570            580           590            600          610
WAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSK
616 620            630            640            650           660            670          680
EGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCR
no	  2° structure α-­‐helix β-­‐strand
turnβ-­‐bridge peptic	  peptide
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TRESI-HDX was carried out on a microfluidic device that facilitates variable HDX 
labeling times from 179 ms to 7.56 s, with on-chip digestion and electrospray ionization. 
Digestion of STAT3 was reasonably efficient in our system, resulting in sequence 
coverage of 71% corresponding to 53 unique peptides and an average spatial resolution 
of 5.1 amino acids (Fig. 15). Typical HDX MS data is depicted in Fig. 16A for STAT3 
peptides that experienced no change in deuteration, increased deuteration or 
decreased deuteration as a result of complexation with SF-1-066 and BP-1-102 STAT3 
inhibitors. Kinetic profiles, depicting the change in peptide deuteration as a function of 
labeling time, are shown in Fig. 16B.  Data were normalized fit to a single exponential, 
and the amplitude parameter was used to calculate deuterium uptake. In Fig. 17, 
deuterium uptake is mapped onto the crystal structure of STAT3 (PDB ID: 1BG1), giving 
a broad picture of the dynamic nature of the free SH2 domain and the changes in 
dynamics that occur upon complexation with inhibitors (Fig. 17A-C). Fig. 18 contains the 
HDX kinetic plots for all the observed peptic peptides in this study. 
3.4.2 Mapping the inhibitor binding site in STAT3 
Mapping the fold-change in deuterium uptake for inhibitor-bound vs. free STAT3 to the 
crystal structure (Fig. 19A and B) enables the visualization of regions exhibiting 
pronounced changes in local backbone dynamics. Decreases in deuterium uptake may 
indicate the steric exclusion of solvent molecules or, alternatively, reorganization of the 
local backbone hydrogen bonding network resulting in a net increase in hydrogen 
bonding. Increases in deuterium uptake typically result from a disruption of secondary 
structure or increased local accessibility to solvent. The STAT3 SH2 domain (Fig. 17A 
and B, insets) exclusively experienced significant, large decreases in deuterium uptake 
upon complexation with both SF-1-066 and BP-1-102 inhibitors, in 5 and 6 unique 
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peptides, respectively. This observation was consistent with the occlusion of the SH2 
phosphotyrosine-binding sub-pockets where the inhibitors are predicted to bind, 
resulting in decreased solvent accessibility. Peptides ISKERERAIL (589-598), LRFSE 
(608-612), and YKIMDATN (657-664), lining the surface of the putative inhibitor binding 
pocket predicted by docking studies, all exhibited a 2-3-fold reduction in deuterium 
uptake when inhibitors were present (Fig. 19A and B). 
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Fig. 16 Analysis of Site-Specific HDX in STAT3. A) Representative spectra of peptic 
peptides derived from STAT3 for non-deuterated STAT3 (top row), STAT3 labeled with 
a 2.8 s HDX pulse (second row), and STAT3 complexed with SF-1-066 (third row) or 
BP-1-102 (bottom row) labeled by a 2.8 s HDX pulse (bottom row). Raw spectra depict 
the observed shifts in isotopic distribution following HDX. Peptides that exhibited an 
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increase (left column), a decrease (right column) or no change (middle column) in 
deuterium uptake are represented. Percent deuterium uptake is indicated on each 
spectrum. B) Normalized HDX kinetic plots of representative peptides in (A) for the free 
STAT3 (open circles), and STAT3 complexed with SF-1-066 (filled squares) or BP-1-
102 (filled triangles). Data represent an average of triplicate runs (error bars represent 
SEM). 
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Fig. 17 Deuterium Uptake Mapped onto the Crystal Structure of STAT3. Average 
deuterium uptake mapped and color-coded onto the crystal structure of STAT3 (PDB 
ID: 1BG1) for A) free STAT3, B) STAT3 complexed with SF-1-066, and C) STAT3 
complexed with BP1-102. STAT3 protein is depicted as a stick representation colored 
by element. Low (blue shading) represents 0-20% deuterium uptake, followed by green 
(20-40%), yellow (40-60%), orange (60-80%), and then high (red shading) representing 
80-100% deuterium uptake. 
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Fig. 18 Kinetic Plots of Deuterium Uptake in Peptic Peptides Derived From STAT3 and 
STAT3-Inhibitor Complexes. For each of the 62 peptic peptides identified, calculated 
percent deuterium uptake is plotted as a function of deuterium labeling time (from 179 
ms to 7.59 s) for the digested STAT3 (open circles), STAT3:SF-1-066 (filled squares) 
and STAT3:BP-1-102 (filled triangles) complexes. Data represent an average of 
triplicate runs (error bars represent SEM).   
80 
 
 
Fig. 19 Fold Changes in Deuterium Uptake of STAT3. Fold changes in deuterium 
uptake are shown for A) STAT3 complexed with SF-1-066 and B) STAT3 complexed 
with BP1-102 are shown. Hotspots of differential deuterium uptake, mapped onto the 
crystal structure of STAT3 (PDB ID: 1BG1), are color-coded as decreases (blue 
shading) or increases (red shading) in uptake. Insets show a magnified view of the SH2 
domain, depicted from the face of the predicted inhibitor-binding pocket.  
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3.4.3 Allosteric Changes Induced in STAT3 by the SH2 Dimerization 
Inhibitors 
Multiple peptides from outside of the SH2 domain exhibited pronounced changes in 
relative deuterium uptake upon complexation with inhibitor (Fig. 19A and B, and Fig. 
20A and B). The majority of these conformational disturbances manifested as significant 
increases in deuterium uptake, and were largely localized to regions of α-helical 
secondary structure. The profile of allosteric differences induced by SF-1-066 versus 
BP-1-102 was somewhat different. Fig. 20C highlights the regions that exhibited relative 
changes in HDX that were significantly different between the SF-1-066 (orange) and 
BP-1-102 (purple) STAT3 complexes. 
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Fig. 20 Fold Changes in Deuterium Uptake for All Peptic Peptides Comprising the 
STAT3 Primary Sequence Coverage in the HDX Experiments. Fold changes in 
deuterium uptake from free STAT3 are shown for A) STAT3 complexed with SF-1-066 
and B) STAT3 complexed with BP1-102. C) Significant differences in relative deuterium 
uptake between the STAT3:SF-1-066 (orange) and STAT3:BP-1-102 (purple) 
complexes are highlighted. Data represent an average of triplicate runs (error bars 
represent SEM). 
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3.5 Discussion 
This study highlights the utility of structural mass spectrometry based on TRESI-
MS/HDX in probing protein-ligand interactions and understanding dynamic changes and 
mechanisms associated with ligand binding. The “bottom-up” HDX approach, as 
implemented here, enables one to generate accurate, sub-second timescale kinetic 
profiles of site-specific exchange in the native protein structures. This structural 
technique is particularly useful for interrogating protein domains with minimal secondary 
structure or high degree of intrinsic disorder. While NMR has been used to probe 
disordered proteins to a degree, it is highly limited by protein size in applications 
involving protein-ligand interactions (19,87). 
Here we applied the microfluidic-integrated TRESI-MS/HDX workflow to derive 
averaged dynamic structures of free and inhibitor-bound STAT3. Our examination of the 
dynamic changes in this protein largely confirmed in silico predictions with respect to the 
inhibitor binding regions, as well as revealed additional regions inside the STAT3 SH2 
domain that exhibit strong protection from exchange due to the interaction with the 
inhibitors. SF-1-066 and BP-1-102 represent a novel, state-of-the-art class of salicylic 
acid-based SH2-targeted STAT3 inhibitors with low micromolar- and nanomolar-range 
affinity for STAT3, yet no experimental evidence directly describes their interaction with 
the SH2 domain (119,121). Additionally, our data reveal a series of increases in HDX 
outside the STAT3 SH2 domain due to inhibitor binding, suggesting allosteric effects 
that are potentially destabilizing to the protein. 
Peptides ISKERERAIL (589-598), LRFSE (608-612), and YKIMDATN (657-664), which 
exhibit significant decreases in deuterium uptake upon inhibitor binding, map to the 
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surface of the inhibitor binding pocket predicted by docking studies (Fig. 20A and B). 
The side-chain of Arg609, mapping near the peptide LRFSE (608-612), was predicted 
to hydrogen bond with the salicylic acid moiety common to both inhibitors, greatly 
stabilizing the binding energy of the molecules (119,120). This is consistent with large 
decreases in backbone deuteration observed in the LRFSE (608-612) peptide given the 
tight predicted occupancy of this sub-pocket by the salicylic acid moiety for both 
inhibitors.  
The peptide YKIMDATN (657-664), lining the cyclohexylbenzyl-binding sub-pocket, only 
experienced a significant decrease in deuterium uptake in the case of the higher affinity 
inhibitor BP-1-102 (Fig. 20A and B). The binding of the cyclohexylbenzyl moiety to the 
predicted sub-pocket is dominated by relatively weak van der Waals interactions (121). 
This observation with respect to the YKIMDATN (657-664) peptide, which lines the 
deepest end of the cyclohexylbenzyl sub-pocket, are consistent with the tighter binding 
of the cyclohexylbenzyl moiety of BP-1-102 compared to SF-1-066 as predicted by in 
silico docking (Fig. 14C). The only structural difference between the two inhibitors is the 
substituent at the sulfonamide end of the molecule, being a tosyl sulfonamide for SF-1-
066 and a pentafluorobenzyl sulfonamide for BP-1-102. Despite this, in the peptide 
lining the relevant sub-pocket, ISKERERAIL (589-598), a significant but similar 
decrease in deuteration was observed, not reflective of any differential effect on the 
backbone amides in this region.  
Other regions of the SH2 domain not immediately lining the surface of the predicted 
inhibitor-binding site also exhibited significant decreases in deuterium uptake upon 
inhibitor binding. Some of these segments interact directly with specific regions of the 
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binding pocket. For example, the peptide SKEGGV (614-619) is located in proximity to 
LRFSE (608-612) peptide that lines the salicylic acid moiety binding sub-pocket, with 
the backbone amide of the Ser 611 making a hydrogen bond with the backbone 
carbonyl of Gly618. Both inhibitors induce a significant decrease in deuterium uptake in 
the SKEGGV (614-619) peptide.  
Overall, the higher-affinity inhibitor, BP-1-102, induced more decreases in deuterium 
uptake compared to SF-1-066 (Fig. 20C). This and other observations of significant 
decreases in deuterium uptake in the SH2 domain suggest that either (i) the inhibitors 
are able to bind to regions of the SH2 domain outside of the in silico predicted binding 
pocket, or (ii) the binding of the inhibitors to the predicted binding pocket results in an 
overall stabilization of and, possibly, the induction of additional secondary structure in a 
large portion of the SH2 domain. We tend to favour the latter possibility given the lack of 
clustered HDX decreases elsewhere in the molecule outside of the SH2 domain that 
would point to non-specific binding by the inhibitors to STAT3.  
Our data suggest that the core of the STAT3 SH2 domain represents a highly dynamic 
network, potentially able to transmit local perturbations in dynamics to distal regions of 
the domain. Indeed, studies of dynamics of SH2 domains of other proteins reveal a 
general, global reduction or stabilization in dynamics in a large portion of the SH2 
domain upon peptide ligand binding resulting in increased rigidity that propagates 
throughout the entire domain (59,126). Overall, the clustering of significant decreases in 
deuterium uptake in the SH2 domain of inhibitor-complexed STAT3 provides 
experimental evidence supporting the SH2 domain being the target site of the salicylic 
acid-based inhibitors, SF-1-066 and BP-1-102. This finding corroborates in silico 
87 
 
docking predictions, as well as other experimental evidence. In fluorescence 
polarization assays with STAT3 and a fluorescently labeled phosphotyrosine peptide (5-
carboxyfluorescein-GpYLPQTV-NH2) that mimics the natural SH2 domain target 
substrate, both SF-1-066 and BP-1-102 inhibitors competed strongly with substrate 
binding with an IC50 of 20 µM and 4.1 µM, respectively (119,125). 
 Interestingly, both inhibitors induced a burst of dynamic changes, mainly 
manifesting as significant relative increases in deuterium uptake, outside of the SH2 
domain of STAT3 (Fig. 20A and B). These allosteric changes, induced in the inhibitor-
complexed structures, propagate into STAT3 domains and regions involved in DNA 
binding (β-barrel and connector domains) and nuclear localization of the protein (4-helix 
bundle and β-barrel domains) (124,127). Interestingly, the majority of allosteric changes 
mapped to (or near) regions important to the DNA binding activity of STAT3 (DNA 
binding domain, residues 406-514) (76). The backbone amide of Val432, for instance, is 
directly involved in DNA binding and Glu435 forms a hydrogen bond that is important for 
the maintaining the structural rigidity of one of the DNA binding loops (124). We observe 
a significant increase in deuterium uptake in the peptide IVTEEL (431-436) with both 
inhibitors. This suggests the possibility that the salicylic acid-based inhibitors SF-1-066 
and BP-1-102 could also be acting via an allosteric mechanism to modulate DNA 
binding of STAT3 – a prediction that will need to be explored experimentally with the 
use of STAT3 mutants.  
 The vast majority of allosteric changes induced by inhibitor binding (Fig. 20A and 
B) mapped to regions predicted to have α-helical secondary structure (Fig. 15). 
Increases in HDX in α-helical regions are most likely to result from the loss or 
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remodelling of secondary structure affecting the hydrogen bonding network. STAT3 
complexed with SF-1-066 exhibited more allosteric effects (Fig. 20C) compared to the 
BP-1-102 complex. Allosteric changes were not observed in any peptides derived from 
the MBP protein that was fused via a poly-asparagine (Asn) linker to the N-terminus of 
the STAT3 in our construct (data not shown). This confirms that changes induced by the 
binding of SF-1-066 and BP-1-102 inhibitors to STAT3 outside the SH2 domain are not 
a result of experimental error.  
 Allosteric modulation is an important mechanism of communication between 
distinct domains within the protein and exactly how the information is transmitted 
between domains is an area of active investigation (128). The ability of the SH2 domain 
to induce conformational changes in other domains in the same protein has been 
demonstrated for the C-terminal Src (Csk) kinase (129), a protein tyrosine kinase that 
phosphorylates other kinases of the Src family. In Csk, the binding of the SH2 domain 
target peptide, Csk-binding protein (Cbp), appears to induce conformational changes 
that are transmitted through the SH2 linker to the active site and other regions of the 
protein. Conversely, binding of Csk nucleotide substrates to the kinase domain was 
shown to impact HDX protection in other region of the protein, including the SH2 
domain, depending on the nature of the nucleotide present (130). Our study adds to the 
work of others examining allosteric modulation by HDX MS (83,131,132), highlighting 
the vast utility of this structural technique in probing the evolution of allosteric changes 
in intact proteins under physiological conditions. 
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3.6 Conclusions 
In summary, in silico-predicted interactions of SF-1-066 and BP-1-102 inhibitors with 
regions of the STAT3 SH2 domain were experimentally confirmed by analyzing changes 
in site-specific deuterium uptake upon STAT3 complexation with the inhibitors. Showing 
a large contiguous decrease in deuterium uptake around the putative SH2 domain-
binding site, our data support a mechanism of inhibition driven by ‘pacification’ of the 
SH2 domain through complexation. This compliments prior biochemical evidence that 
points to disruption of STAT3 dimerization as the primary inhibitory mechanism.  
Significant allosteric changes in deuterium uptake were also observed in other STAT3 
domains. Our study highlights the incremental benefits of dynamic structure analysis to 
understanding protein-ligand interactions via the examination of conformational 
ensembles rather than static representations of the protein complex structures. The 
specific findings provide structure-activity insights that would facilitate the design of 
more potent next-generation dimerization inhibitors of STAT3, for instance by amplifying 
desirable allosteric effects. Our methodology could be extended to the study of other 
protein-drug complexes and paves a new avenue for a rapid, sensitive, and affordable 
analysis to support drug development efforts in medicinal chemistry. 
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3.7 TRESI-MS HDX Analysis of the STAT3 Complex with a New 
Tetrapodal Salicylic Acid-Based Inhibitor, BP-5-087  
(This section was adapted from Eiring, A.M., Page, B.G., Kraft, I.L., Mason, C.C., 
Vellore, N.M., Resetca, D., Zabriskie, M.S., Zhang, T.Y., Khorashad, J.S., Engar, A.J., 
Reynolds, K.R., Anderson, D.J., Senina, A., Pomicter, A.D., Arpin, C.C., Ahmad, S., 
Heaton, W.L., Tantravahi, S., Moriggl, R., Wilson, D.J., Baron, R., O’Hare, T., Gunning, 
P.T., and Deininger, M.W. “Combined STAT3 and BCR-ABL1 Inhibition Induces 
Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia” submitted to 
Leukemia.) 
Analogously to the studies described above, the interaction of STAT3 with a novel, 
tetrapodal STAT3 inhibitor, BP-5-087, was probed by TRESI-MS HDX. BP-5-087 is a 
derivative of SF-1-066, with the addition of an ortho-methyl benzyl and trifluoro-methyl 
functional groups (Fig. 21). To map the amino acid residues that are important for BP-5-
087 activity, interactions of BP-5-087 with the STAT3 SH2 domain were experimentally 
confirmed by analyzing changes in site-specific deuterium uptake upon inhibitor binding. 
The structural transitions that occur in STAT3 upon its association with BP-5-087 were 
examined by graphing fold changes in deuterium exchange for each peptic peptide 
detected in STAT3 and the STAT3:BP-5-07 complex (Fig. 22). In three independent 
replicates, the data confirmed that the binding epitope for BP-5-087 is located within the 
STAT3 SH2 domain of the protein (Fig. 22). Fold changes in deuterium uptake were 
analyzed for 68 peptic peptides of STAT3 mapped onto the X-ray crystal structure of 
STAT3 (Fig. 22A). Significant decreases in deuterium uptake clustered almost 
exclusively to the STAT3 SH2 domain, indicating exclusion of solvent molecules or the 
formation of new backbone hydrogen bonds in this region (Fig. 22B). The most 
pronounced decreases in deuterium uptake were observed in peptic peptides that line 
the BP-5-087 salicylic acid-binding and trifluoro-methyl-benzene-binding sub-pockets of 
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the SH2 domain. However, the HDX experiment sequence coverage did not extend to 
peptides lining the BP-5-087 cyclohexylbenzyl-binding sub-pocket. A number of 
significant decreases in deuterium uptake were observed in SH2 domain regions 
proximal to the predicted BP-5-087 sub-pockets, which may be a result of propagating, 
allosteric changes in STAT3 dynamics induced by drug binding. These data provide 
additional support for the putative binding site of salicylic acid-based STAT3 inhibitors of 
dimerization being located in the SH2 domain of the protein, and highlight the robust 
and reproducible nature of HDX experiments in application to binding-epitope mapping 
in protein-ligand interactions. 
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Fig. 21 BP-5-087 Chemical Structure.  
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Fig. 22 Fold Changes in Deuterium Uptake of STAT3 and STAT3:BP-5-087 Complex. 
A) Fold changes in deuterium uptake observed by site-specific TRESI-MS/HDX 
following complexation of STAT3 with BP-5-087 (1:7 molar ratio) color-coded onto the 
STAT3 X-ray crystal structure (PDB ID: 1BG1). Select surface-exposed residues 
mapping to peptic peptides that experience a significant decrease in HDX are indicated 
on the enlarged region that depicts the SH2 domain on the surface of the predicted BP-
5-087 binding site. B) Relative changes in deuterium uptake observed by TRESI-
MS/HDX following complexation of STAT3 protein with BP-5-087 mapped onto the 
primary sequence of STAT3 and grouped by domain. Changes considered significant 
(>25%) are highlighted by darker colors. Site-specific TRESI-MS/HDX data from three 
independent repeats. Error bars represent SEM. 
 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
0.25
0.5
0.75
1
1.25
1.5
1.75
12
9(
13
6
14
0(
14
5
14
2(
14
5
14
3(
14
8
17
5(
17
9
19
3(
20
4
19
9(
20
3
20
6(
22
2
20
8(
21
2
22
3(
23
0
23
0(
23
5
23
8(
24
4
24
1(
24
7
24
3(
25
5
25
8(
26
3
26
1(
26
7
26
7(
27
0
27
1(
27
6
27
6(
28
0
28
0(
28
9
28
9(
30
0
29
4(
30
7
30
7(
31
2
30
8(
31
2
31
7(
32
1
32
1(
33
4
34
6(
35
1
35
2(
35
7
35
3(
35
7
37
3(
38
1
37
9(
38
7
41
1(
42
5
42
5(
43
0
43
1(
43
6
43
9(
44
2
44
5(
45
0
45
5(
45
3
46
4(
46
8
47
0(
47
5
47
6(
48
1
47
9(
48
2
49
3(
50
1
50
6(
51
0
50
9(
51
2
51
3(
52
5
51
9(
52
9
52
4(
53
2
52
9(
53
8
52
9(
53
9
53
0(
53
3
54
4(
54
9
55
6(
56
4
57
8(
58
4
58
3(
58
6
58
5(
59
0
58
9(
59
8
59
9(
60
7
60
8(
61
2
61
4(
61
9
64
3(
64
7
65
7(
66
1
65
7(
66
4
66
7(
67
2
66
7(
67
3
67
4(
68
2
68
2(
68
8
68
3(
68
8
68
4(
68
7
A!
B!
Fo
ld
%D
eu
te
riu
m
%U
pt
ak
e%
Di
ffe
re
nc
e%
SH2%Connector%β8Barrel%48Helix%Bundle%
D661 
R595 
K591 
S611 
E616 
94 
 
Chapter 4  
 Conclusions and Future Directions 4
4.1 Conclusions 
The body of work summarized in this thesis extends the application of site-specific 
TRESI-MS HDX implemented on a microfluidic device to the study of the dynamics of 
protein-ligand interactions and binding epitope mapping on native protein complexes in 
solution. The implementation of TRESI-MS HDX based on a rapid-mixer on the 
microfluidic device, described in this work, enables the entire HDX “bottom-up” workflow 
to be carried out continuously with online coupling directly to the ESI-MS ionization 
source. The introduction to this thesis (Chapter 1) reviews the construction and 
operation of the HDX microfluidic device, and its existing applications in the 
investigation of dynamics of protein unfolding, enzyme catalysis, allosteric regulation in 
enzyme turnover, and characterization of weakly structured regions. In Chapter 2, the 
HDX microfluidic device was utilized to map and characterize the GSH ligand-binding 
site of GST. In the context of the predominantly “lock-and-key” type binding in this 
model, comparative HDX analyses of free GST and GST complexed to GSH readily and 
clearly revealed the GSH binding region, supporting the totality of X-ray crystallography 
data on this protein system. Two of the peptic peptides of GST are predicted to make 
new backbone hydrogen bonds with GSH upon its binding to the protein, and were 
readily visible in HDX experiments, manifesting in pronounced decreases in deuterium 
uptake that imply the exclusion of solvent molecules and stabilization of the binding site. 
In Chapter 3, the ligand-binding site of a much larger protein, STAT3 (~ 66 kDa), was 
mapped by HDX for a number of STAT3-inhibitor complexes. Data generated from 
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these HDX experiments supported the in silico predictions localizing the binding site of 
the novel salicylic acid-based inhibitors, SF-1-066, BP-1-102, and BP-5-087, to the SH2 
domain of STAT3. TRESI-MS HDX successfully characterized the dynamics of inhibitor 
binding to STAT3 and revealed a series of allosteric changes propagating form the SH2 
domain to other STAT3 domains important for this protein’s function. The HDX data 
form STAT3 support a more complex, “induced-fit” type ligand binding, with major and 
minors structural reorganization in the protein. This study highlights the general utility of 
HDX in medicinal chemistry for facilitating lead screening and SAR studies.  
The types of applications of microfluidic device-implemented TRESI-MS HDX, detailed 
in this thesis, highlight the universal applicability and versatility of this technique to 
probing the sub-second timescale dynamics of protein-ligand interactions. Compared to 
the previous implementations of HDX in this context, the microfluidic device-based 
technique that permits the integration of the entire HDX workflow, labelling, quenching 
and digestion, for continuous-mode operation is highly accurate and reproducible. HDX 
MS experiments are seeing a steep increase in popularity in applications in both 
structural biology research and industry, for quality assurance of therapeutic biologicals 
and biosimilars, and drug development. In the study of protein-ligand interactions in 
particular, HDX MS experiments are very attractive owing to their favorable speed of 
implementation and universal adaptability to different model systems, compared to other 
structural biology techniques. 
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4.2 Future Directions 
Time resolved HDX MS is a highly versatile and universally applicable technique. In this 
thesis, the application of TRESI-MS HDX for site-specific analysis of protein dynamics 
to the interrogation of protein ligand interactions was comprehensively described. Given 
the increasing interest in understanding complex protein-protein interactions in 
molecular and structural biology and proteomics research, the extension of site-specific 
TRESI-MS HDX implementation to the interrogation of protein-protein interaction 
dynamics is highly desired and imminent. The current work lays the foundation for 
protein-protein interaction studies by TRESI-MS HDX, and is a challenge that scales 
linearly in difficulty. The major hurdle in extending this technique as described to the 
study of complexes consisting of two or more distinct proteins lies in the ability to 
accurately identify the correct peptic peptides, once the MS spectra increases in 
complexity, crowded by the presence of peptic peptides derived form multiple species. 
An additional dimension of peptide separation to decrease spectrum complexity could 
be provided by integration with IMS. Furthermore, the microfluidic device can be 
integrated online to HPLC, which would greatly enhance peptide separation, but has 
been shown to significantly increase in back-exchange of the labile deuterated 
backbone amides.    
Another clear advantage of HDX MS implemented on a microfluidic device lies in the 
ability to utilize it for high-throughput screening (HTS) applications. Compared to the 
current experimental applications of other structural biology techniques, such as NMR, 
where HTS is difficult to implement, the microfluidic set-up of TRESI-MS HDX enables 
high-throughput and multiplexing. The ability of HDX to simultaneously probe changes 
97 
 
in protein dynamics globally could be utilized in the study and further development of 
molecular chaperons, which has applications in a multitude of disease indications where 
protein misfolding causes pathology, such as lysosomal storage disorders and CNS 
disorders and diseases. TRESI-MS HDX can be a great tool for examining changes in 
the conformational ensembles of the target protein as it interacts with a chaperon, 
providing an additional level of structural resolution not readily available with other 
biophysical and bioanalytical techniques currently utilized for such studies. 
Improvements to the time-resolution of HDX will further facilitate the detection of 
molecular chaperons that induce very subtle effects in the target proteins.  
In summary, the study of protein-ligand and protein-protein interactions by HDX is a 
new and vastly unexplored paradigm. Advances in the development of techniques, 
instrumentation, and computational tools for streamlined HDX analysis will fuel an 
increased interest in the application of HDX to expand on the enormous amount of 
knowledge and structural data derived by X-ray crystallography and NMR with the 
protein dynamics-based interpretation of biological interactions, mechanisms, and 
function.   
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